




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C07D 401/00		A2	(11) International Publication Number: WO 00/39114
			(43) International Publication Date: 6 July 2000 (06.07.00)
(21) International Application Number: PCT/US99/27953	(22) International Filing Date: 21 December 1999 (21.12.99)	(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, NO, NZ, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UZ, VN, YU, ZA, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
(30) Priority Data: 09/220,316 23 December 1998 (23.12.98) US		(23) Priority Data: 09/220,316 23 December 1998 (23.12.98) US	
(71) Applicant: SCHERING CORPORATION [US/US]; 2000 Galloping Hill Road, Kenilworth, NJ 07033-0530 (US).	(72) Inventors: REICHARD, Gregory, A.; 4 Bahama Road, Morris Plains, NJ 07950 (US). SHIH, Neng-Yang; 1 Maple Drive, North Caldwell, NJ 07006 (US). WANG, Dasong; 941 Savitt Place, Apt. 3, Union, NJ 07083 (US).	(74) Agents: MAGATTI, Anita, W. et al.; Schering-Plough Corporation, Patent Dept. K-6-1 1990, 2000 Galloping Hill Road, Kenilworth, NJ 07033-0530 (US).	(44) Publication Date: 6 July 2000 (06.07.00)
			Published <i>Without international search report and to be republished upon receipt of that report.</i>

(54) Title: SUBSTITUTED OXIMES AND HYDRAZONES AS NEUROKININ ANTAGONISTS



(57) Abstract

Compound represented by structural formula (I) or a pharmaceutical acceptable salt thereof, wherein a is 0-3; b, d and e are 0-2; R is H, alkyl, F or -OR⁶; A is an optionally substituted oxime or hydrazone; d is not 0 and X is a bond, -C(O)-, -O-, -NR⁹-, -S(O)_e-, -N(R⁶)C(O)-, -C(O)N(R⁶)-, -OC(O)NR⁶-, -OC(=S)NR⁶-, -N(R⁶)C(=S)O-, -S(O)N(R⁶)-, -N(R⁶)S(O)O-, -N(R⁶)C(O)O-, -OC(O)- or -N(R⁶)C(O)NR⁷-; or d is 0 and X is a bond or -NR⁶-; T is H, aryl, heterocycloalkyl or heteroaryl; Q is phenyl, napthyl or heteroaryl; R⁶ is H, alkyl, hydroxyalkyl, alkoxyalkyl, phenyl, and benzyl; R⁹ is R⁶ or -OR⁶, R^{6a}, R^{7a}, R^{8a} and R^{9a} are H or alkyl; Z is a nitrogen-containing heterocyclo group, e.g., piperidinyl, substituted by a heterocyclo- or heterocycloalkyl group; wherein phenyl, benzyl, aryl, heterocycloalkyl, heteroaryl and cycloalkyl groups are optionally substituted; methods of treating diseases such as asthma, cough, bronchospasm, depression, emesis, inflammatory diseases, and gastrointestinal disorders with said compounds, and pharmaceutical compositions comprising said compounds are disclosed.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

10

SUBSTITUTED OXIMES AND HYDRAZONES AS NEUROKININ ANTAGONISTS

BACKGROUND OF THE INVENTION

15 The present invention relates to a genus of substituted oximes and hydrazones useful as antagonists of tachykinin receptors, in particular as antagonists of the neuropeptides neurokinin-1 receptor (NK₁) and/or neurokinin-2 receptor (NK₂) and/or neurokinin-3 receptor (NK₃).

20 Neurokinin receptors are found in the nervous system and the circulatory system and peripheral tissues of mammals, and therefore are involved in a variety of biological processes. Neurokinin receptor antagonists are consequently expected to be useful in the treatment or prevention of various mammalian disease states, for example asthma, cough, bronchospasm, inflammatory diseases such as arthritis, central nervous system conditions such as migraine and epilepsy, nociception, 25 depression, and various gastrointestinal disorders such as Crohn's disease.


30 In particular, NK₁ receptors have been reported to be involved in microvascular leakage and mucus secretion, and NK₂ receptors have been associated with smooth muscle contraction, making NK₁ and NK₂ receptor antagonists especially useful in the treatment and prevention of asthma.

Substituted oxime and hydrazone NK₁ and NK₂ receptor antagonists have previously been disclosed in U.S. 5,696,267, U.S. 5,688,960, and U.S. 5,789,422.

35 SUMMARY OF THE INVENTION

Compounds of the present invention are represented by the formula I

- 2 -



or a pharmaceutically acceptable salt thereof, wherein:

- a is 0, 1, 2 or 3;
- b and d are independently 0, 1 or 2;
- 5 R is H, C₁₋₆ alkyl, -OR⁶ or -F;
- A is =N-OR¹ or =N-N(R²)(R³);
- when d is not 0, X is a bond, -C(O)-, -O-, -NR⁹-, -S(O)e-, -N(R⁶)C(O)-, -C(O)N(R⁶)-, -OC(O)NR⁶-, -OC(=S)NR⁶-, -N(R⁶)C(=S)O-, -S(O)₂N(R⁶)-, -N(R⁶)S(O)₂-, -N(R⁶)C(O)O-, -OC(O)- or -N(R⁶)C(O)NR⁷;
- 10 and
- when d is 0, X is a bond or -NR⁶-;
- T is H, R⁴-aryl, R⁴-heterocycloalkyl or R⁴-heteroaryl;
- Q is R⁵-phenyl, R⁵-naphthyl or R⁵-heteroaryl;
- R¹ is H, C₁₋₆ alkyl, -(C(R⁶)(R⁷))_n-G, -G², -(C(R⁶)(R⁷))_p-M-(C(R¹³)(R¹⁴))_n-G or -(C(R⁶)(R⁷))_p-M-(R⁴-heteroaryl);
- 15 R² and R³ are independently selected from the group consisting of H, C₁₋₆ alkyl, -(C(R⁶)(R⁷))_n-G, -G² and -S(O)eR¹³; or R² and R³, together with the nitrogen to which they are attached, form a ring of 5 to 6 members, wherein 0, 1 or 2 ring members are selected from the group consisting of -O-, -S- and -N(R¹⁹)-;
- 20 R⁴ and R⁵ are independently 1-3 substituents independently selected from the group consisting of H, halogeno, -OR⁶, -OC(O)R⁶, -OC(O)N(R⁶)(R⁷), -N(R⁶)(R⁷), C₁₋₆ alkyl, -CF₃, -C₂F₅, -COR⁶, -CO₂R⁶, -CON(R⁶)(R⁷), -S(O)eR¹³, -CN, -OCF₃, -OCHF₂, -NR⁶CO₂R¹⁶, -NR⁶COR⁷, -NR⁸CON(R⁶)(R⁷), NO₂, -N(R⁶)S(O)₂R¹³ or -S(O)₂N(R⁶)(R⁷); or adjacent R⁴ substituents or adjacent R⁵ substituents can form a -O-CH₂-O- group;
- 25 R⁶, R⁷, R⁸, R¹³ and R¹⁴ are independently selected from the group consisting of H, C₁₋₆ alkyl, C₂-C₆ hydroxyalkyl, C₁-C₆ alkoxy-C₁-C₆ alkyl, R¹⁵-phenyl, and R¹⁵-benzyl;
- 30 R⁹ is independently selected from the group consisting of R⁶ and -OR⁶;
- or R⁶ and R⁷, or R⁷ and R⁹, together with the nitrogen to which they are attached, form a ring of 5 to 6 members, wherein 0, 1 or 2 ring members are selected from the group consisting of -O-, -S- and -N(R¹⁹)-;

- 3 -

R^{6a}, R^{7a}, R^{8a}, R^{9a}, R¹⁰ and R^{10a} are independently selected from the group consisting of H and C₁₋₆ alkyl;

R¹⁵ is 1 to 3 substituents independently selected from the group consisting of H, -OH, C_{1-C₆} alkyl, C_{1-C₆} alkoxy, C_{1-C₆} alkylthio, halogeno,

5 -CF₃, -C₂F₅, -COR¹⁰, -CO₂R¹⁰, -C(O)N(R¹⁰)₂, -S(O)_eR^{10a}, -CN, -N(R¹⁰)COR¹⁰, -N(R¹⁰)CON(R¹⁰)₂ and -NO₂;

R¹⁶ is C₁₋₆ alkyl, R¹⁵-phenyl or R¹⁵-benzyl;

R¹⁹ is H, C_{1-C₆} alkyl, -C(O)N(R¹⁰)₂ or -CO₂R¹⁰;

n and p are independently 1-6;

10 G is selected from the group consisting of H, R⁴-aryl, R⁴-hetero-cycloalkyl, R⁴-heteroaryl, R⁴-cycloalkyl, -CH₂F, -CHF₂, -CF₃, -OR⁶, -N(R⁶)(R⁷), -COR⁶, -CO₂R⁶, -CON(R⁷)(R⁹), -S(O)_eR¹³, -NR⁶CO₂R¹⁶, -NR⁶COR⁷, -NR⁸CON(R⁶)(R⁷), -N(R⁶)S(O)₂R¹³, -N(R⁶)S(O)₂N(R³³)(R³⁴), -S(O)₂N(R⁶)(R⁷), -OC(O)R⁶, -OC(O)N(R⁶)(R⁷), -C(=NOR⁸)N(R⁶)(R⁷),

15 -C(=NR²⁵)N(R⁶)(R⁷), -N(R⁸)C(=NR²⁵)N(R⁶)(R⁷), -CN, -C(O)N(R⁶)OR⁷, and -C(O)N(R⁹)-(R⁴-heteroaryl), provided that when n is 1, G is not -OH or -N(R⁶)(R⁷);

M is selected from the group consisting of a double bond, -O-, -N(R⁶)-, -C(O)-, -C(R⁶)(OR⁷)-, -C(R⁸)(N(R⁶)(R⁷))-, -C(=NOR⁶)N(R⁷)-, -C(N(R⁶)(R⁷))=NO-, -C(=NR²⁵)N(R⁶)-, -C(O)N(R⁹)-, -N(R⁹)C(O)-,

20 -C(=S)N(R⁹)-, -N(R⁹)C(=S)- and -N(R⁶)C(O)N(R⁷)-, provided that when n is 1, G is not OH or -NH(R⁶); and when p is 2-6, M can also be -N(R⁶)C(=NR²⁵)N(R⁷)- or -OC(O)N(R⁶)-;

G² is R⁴-aryl, R⁴-heterocycloalkyl, R⁴-heteroaryl, R⁴-cycloalkyl, -COR⁶, -CO₂R¹⁶, -S(O)₂N(R⁶)(R⁷) or -CON(R⁶)(R⁷);

25 e is 0, 1 or 2, provided that when e is 1 or 2, R¹³ and R^{10a} are not H; R²⁵ is H, C_{1-C₆} alkyl, -CN, R¹⁵-phenyl or R¹⁵-benzyl;

Z is

30

g, h and j are independently 0-2;

- 4 -

k is 1-4;
 X¹ is -O-, -S- or -NR⁹-;
 J is =O, =S, =NR⁹, =NCN or =NOR¹;
 J¹ and J² are independently selected from the group consisting of
 5 two hydrogen atoms, =O, =S, =NR⁹ and =NOR¹;
 R²⁶, R²⁷ and R²⁹ are independently selected from the group
 consisting of H, C₁₋₆ alkyl, -(C(R⁶)(R⁷))_n-G, -G², -C(O)-(C(R⁸)(R⁹))_n-G and
 -S(O)_eR¹³;
 R²⁸ is H, -(C(R⁶)(R⁷))_t-G or -CON(R⁶)(R⁷);
 10 t is 0, 1, 2 or 3, provided that when j is 0, t is 1, 2 or 3;
 R³⁰ is 1-3 substituents independently selected from the group
 consisting of H, halogeno, -OR⁶, -OC(O)R⁶, -OC(O)N(R⁶)(R⁷), -N(R⁶)(R⁷),
 C₁₋₆ alkyl, -CF₃, -C₂F₅, -COR⁶, -CO₂R⁶, -CON(R⁶)(R⁷), -S(O)_eR¹³, -CN,
 -OCF₃, -NR⁶CO₂R¹⁶, -NR⁶COR⁷, -NR⁸CON(R⁶)(R⁷), NO₂,
 15 -N(R⁶)S(O)₂R¹³ or -S(O)₂N(R⁶)(R⁷); or adjacent R³⁰ substituents can form
 a -O-CH₂-O- group;
 R³¹ is independently selected from the group consisting of H and
 C₁-C₆ alkyl;
 R³² is independently selected from the group consisting of H, -OH
 20 and C₁-C₆ alkoxy; and
 R³³ and R³⁴ are independently selected from the group consisting of
 H, C₁-C₆ alkyl, R¹⁵-phenyl and R¹⁵-benzyl.


 Preferred are compounds of formula I wherein X is -O-, -C(O)-, a
 25 bond, -NR⁶-, -S(O)_e-, -N(R⁶)C(O)-, -OC(O)NR⁶ or -C(=NOR¹)-. More
 preferred are compounds of formula I wherein X is -O-, -NR⁶-, -N(R⁶)C(O)-
 or -OC(O)NR⁶. Additional preferred definitions are: b is 1 or 2 when X is -
 O- or -N(R⁶)-; b is 0 when X is -N(R⁶)C(O)-; and d is 1 or 2. T is
 30 preferably R⁴-aryl, with R⁴-phenyl being more preferred. Also preferred are
 compounds wherein R^{6a}, R^{7a}, R^{8a} and R^{9a} are independently hydrogen,
 hydroxyalkyl or alkoxyalkyl, with hydrogen being more preferred.
 Especially preferred are compounds wherein R^{8a} and R^{9a} are each
 35 hydrogen, d and b are each 1, X is -O-, -NR⁶-, -N(R⁶)C(O)- or -OC(O)NR⁶,
 T is R⁴-aryl and R⁴ is two substituents selected from C₁-C₆ alkyl, halogeno,
 -CF₃ and C₁-C₆ alkoxy.

Also preferred are compounds of formula I wherein R is hydrogen.
 Q is preferably R⁵-phenyl; an especially preferred definition for Q is R⁵-
 phenyl, wherein R⁵ is two halogeno substituents.

- 5 -


Preferred are compounds of formula I wherein A is =N-OR¹. R¹ is preferably H, alkyl, -(CH₂)_n-G, -(CH₂)_p-M-(CH₂)_n-G or -C(O)N(R⁶)(R⁷), wherein M is -O- or -C(O)N(R⁹)- and G is -CO₂R⁶, -OR⁶, -C(O)N(R⁷)(R⁹), -C(=NOR⁸)N(R⁶)(R⁷), -C(O)N(R⁹)(R⁴-heteroaryl) or R⁴-heteroaryl. When A is =N-N(R²)(R³), R² and R³ are independently preferably H, C₁-C₆ alkyl, -(C(R⁶)(R⁷))_n-G or G².

Preferred definitions of Z are



Variables g and h are preferably each 1; J is preferably =O; j is preferably 0; k is preferably 1 or 2; and R²⁸ is preferably H.

A more preferred definition of Z is



wherein k is preferably 1 or 2.

This invention also relates to the use of a compound of formula I in the treatment of for example respiratory diseases such as chronic lung disease, bronchitis, pneumonia, asthma, allergy, cough, bronchospasm; inflammatory diseases such as arthritis and psoriasis; skin disorders such as atopic dermatitis and contact dermatitis; ophthalmological disorders such as retinitis, ocular hypertension and cataracts; addictions such as alcohol dependence and stress related disorders; central nervous system conditions such as anxiety, migraine, epilepsy, nociception, emesis, depression, psychosis, schizophrenia, Alzheimer's disease, AIDS related dementia and Towne's disease; gastrointestinal disorders such as Crohn's disease and colitis; bladder disorders; atherosclerosis; fibrosing disorders; and obesity.

In another aspect, the invention relates to a pharmaceutical composition comprising a compound of formula I in a pharmaceutically acceptable carrier. The invention also relates to the use of said pharmaceutical composition in the treatment of the mammalian disease states listed above.

DETAILED DESCRIPTION

As used herein, the term "alkyl" means straight or branched alkyl chains. "Lower alkyl" refers to alkyl chains of 1-6 carbon atoms and, similarly, lower alkoxy refers to alkoxy chains of 1-6 carbon atoms.

5 "Cycloalkyl" means cyclic alkyl groups having 3 to 6 carbon atoms.

"Aryl" means phenyl, naphthyl, indenyl, tetrahydronaphthyl, indanyl, anthracenyl or fluorenyl.

"Halogeno" refers to fluoro, chloro, bromo or iodo atoms.

10 "Heterocycloalkyl" refers to 4- to 6-membered saturated rings comprising 1 to 3 heteroatoms independently selected from the group consisting of -O-, -S- and -N(R¹⁹)-, with the remaining ring members being carbon. Examples of heterocycloalkyl rings are tetrahydrofuranyl, pyrrolidinyl, piperidinyl, morpholinyl, thiomorpholinyl and piperazinyl. R⁴-heterocycloalkyl refers to such groups wherein substitutable ring carbon atoms have an R⁴ substituent.

15 "Heteroaryl" refers to 5- to 10-membered single or benzofused aromatic rings comprising 1 to 4 heteroatoms independently selected from the group consisting of -O-, -S- and -N=, provided that the rings do not include adjacent oxygen and/or sulfur atoms. Examples of single-ring heteroaryl groups are pyridyl, isoxazolyl, oxadiazolyl, furanyl, pyrrolyl, thienyl, imidazolyl, pyrazolyl, tetrazolyl, thiazolyl, thiadiazolyl, pyrazinyl, pyrimidinyl, pyridazinyl and triazolyl. Examples of benzofused heteroaryl groups are indolyl, quinolinyl, thianaphthenyl and benzofurazanyl. N-oxides of nitrogen-containing heteroaryl groups are also included. All 20 positional isomers are contemplated, e.g., 1-pyridyl, 2-pyridyl, 3-pyridyl and 4-pyridyl. R⁴-heteroaryl refers to such groups wherein substitutable ring carbon atoms have an R⁴ substituent.

25 Where R² and R³, or R⁶ and R⁷ substituents on a nitrogen atom form a ring and additional heteroatoms are present, the rings do not include adjacent oxygen and/or sulfur atoms or three adjacent heteroatoms. Typical rings so formed are morpholinyl, piperazinyl and piperidinyl.

30 In the above definitions, wherein variables R⁶, R⁷, R⁸, R¹³, R¹⁴, R¹⁵, R³⁰, R³¹ and R³², for example, are said to be independently selected from a group of substituents, we mean that R⁶, R⁷, R⁸, R¹³, R¹⁴, R¹⁵, R³⁰, R³¹ and R³² are independently selected, but also that where an R⁶, R⁷, R⁸, R¹³, R¹⁴, R¹⁵, R³⁰ R³¹ or R³² variable occurs more than once in a molecule, those occurrences are independently selected (e.g., if R is -OR⁶ wherein R⁶ is hydrogen, X can be -N(R⁶)- wherein R⁶ is ethyl). Similarly,

- 7 -

R⁴ and R⁵ can be independently selected from a group of substituents, and where more than one R⁴ and R⁵ are present, the substituents are independently selected; those skilled in the art will recognize that the size and nature of the substituent(s) will affect the number of substituents which can be present.

Compounds of formula I can have at least one asymmetrical carbon atom and all isomers, including diastereomers, enantiomers and rotational isomers, as well as E and Z isomers of the oxime, hydrazone and olefin groups, are contemplated as being part of this invention. The invention includes d and l isomers in both pure form and in admixture, including racemic mixtures. Isomers can be prepared using conventional techniques, either by reacting optically pure or optically enriched starting materials or by separating isomers of a compound of formula I.

Those skilled in the art will appreciate that for some compounds of formula I, one isomer will show greater pharmacological activity than other isomers.

Compounds of the invention have at least one amino group which can form pharmaceutically acceptable salts with organic and inorganic acids. Examples of suitable acids for salt formation are hydrochloric, sulfuric, phosphoric, acetic, citric, oxalic, malonic, salicylic, malic, fumaric, tartaric, succinic, ascorbic, maleic, methanesulfonic and other mineral and carboxylic acids well known to those in the art. The salt is prepared by contacting the free base form with a sufficient amount of the desired acid to produce a salt. The free base form may be regenerated by treating the salt with a suitable dilute aqueous base solution such as dilute aqueous sodium bicarbonate. The free base form differs from its respective salt form somewhat in certain physical properties, such as solubility in polar solvents, but the salt is otherwise equivalent to its respective free base forms for purposes of the invention.

Certain compounds of the invention are acidic (e.g., those compounds which possess a carboxyl group). These compounds form pharmaceutically acceptable salts with inorganic and organic bases. Examples of such salts are the sodium, potassium, calcium, aluminum, gold and silver salts. Also included are salts formed with pharmaceutically acceptable amines such as ammonia, alkyl amines, hydroxyalkylamines, N-methylglucamine and the like.


Compounds of formula I can be prepared using methods well known to those skilled in the art, for example by procedures disclosed in U.S.

- 8 -

5,696,267, incorporated herein by reference. The skilled artisan will recognize that other procedures may be applicable, and that the procedure may be suitably modified to prepare other compounds within the scope of formula I.

5 Compounds of formula I as defined are preferably prepared as shown in the following reaction scheme as disclosed in U.S. 5,696,267. In the reaction scheme, the variables are as defined above :


Step 1:



10 In step 1, a compound of formula 47A, wherein Q is as defined above, is reacted with a base such as lithium diisopropylamide (LDA), KHMDS or KH in an inert organic solvent such as THF or DME to generate a dianion. An acid chloride, ester or amide of formula 46A, 46B, or 46C is added to give a ketone of formula 48. Preferable reaction temperatures 15 ranges from -78°C to 30°C.

20 Alternatively, compounds of formula 48 can be generated by the reaction of a compound of formula 46, preferably 46C, with a metallated species of formula QCH₂Mt where Mt is a metal, such as lithium or MgHal, wherein "Hal" is halogen. The metallated species QCH₂Mt can be generated by conventional procedures, such as treatment compounds of formula QCH₂Hal with Mg or by treating QCH₃ with an organolithium base.

Step 2:




25 In step 2, for compounds wherein R is not hydrogen, the ketone 48 is reacted with a suitable base, such as LDA or KH in an inert organic solvent such as THF. For compounds wherein R is alkyl or hydroxyalkyl, a compound R-R¹⁷"", wherein R¹⁷"" is leaving group such as Br, I or triflate is added. For compounds wherein R is OH, an appropriate oxidizing agent such as dimethyldioxirane or Davis reagent is added. Preferable reaction

- 9 -


temperatures range from -78° to 50°C. For compounds of the present invention wherein R is H, the ketone 48 is used directly in Step 3.

Step 3:




5 In step 3, ketone 49 is reacted with a base such as LDA in a solvent such as THF, then an olefin of formula 50 is added, wherein R^{17a} is as defined above, to give the adduct 51. Preferable reaction temperatures range from -78°C to 60°C.

Step 4:




10 In step 4, ketone 51 is reacted with HA' , wherein A' is $NH-OR^1$, in an organic solvent such as pyridine or ethanol at a temperature from 25°C to 150°C to give a compound of formula 52.

Step 5:



15 In step 5, a compound of formula 52 is oxidized by ozonolysis to give an aldehyde of formula 53. Suitable organic solvents include EtOAc, CH3OH, ethanol, CH2Cl2 or the like. Preferable reaction temperatures are from -78 to 0°C.

20 Step 6:




25 In step 6, an aldehyde of formula 53 is reacted with a compound of formula $Z-H$, wherein Z is as defined above. The reaction is preferably carried out with a suitably substituted amine (as its acid salt e.g. HCl or maleate or as its free base) and a hydride source such as NaBH3CN or sodium triacetoxyborohydride in a suitable solvent (e.g. CH3OH, CH3CH2OH, or CF3CH2OH for NaBH3CN, or THF, 1,2-dichloroethane, CH3CN or CF3CH2OH for triacetoxyborohydride), with 3A sieves to obtain

- 10 -

the desired product. Any suitable temperature can be used with preferable temperatures between 0°C and 25°C.

Alternatively, a compound of formula I can be prepared from 51 by the following reaction scheme, wherein the variables are as defined for the cited U.S. patent:



Compound 51 is oxidized to a compound of formula 54 under conditions similar to those described for step 5 above. The aldehyde of formula 54 is reacted with a compound of formula Z-H in a manner similar to that described in Step 6, and the resultant ketone is then reacted with a compound of the formula HA' as described above in Step 4 to obtain the compound of formula I.

Starting "ZH" groups are known or are made by procedures known in the art. See, for example, the following Preparations 3-12.

Reactive groups not involved in the above processes can be protected during the reactions with conventional protecting groups which can be removed by standard procedures after the reaction. The following Table 1 shows some typical protecting groups:

Table 1

Group to be Protected	Group to be Protected and Protecting Group
$-\text{COOH}$	$-\text{COOalkyl}$, $-\text{COObenzyl}$, $-\text{COOphenyl}$
$>\text{NH}$	$>\text{NCOalkyl}$, $>\text{NCObenzyl}$, $>\text{NCOphenyl}$, $>\text{NCH}_2\text{OCH}_2\text{CH}_2\text{Si}(\text{CH}_3)_3$, $>\text{NC(O)OC(CH}_3)_3$, $>\text{N-benzyl}$, $>\text{NSi}(\text{CH}_3)_3$, $\begin{array}{c} \text{CH}_3 \\ \\ \text{NSi-C(CH}_3)_3 \\ \\ \text{CH}_3 \end{array}$
$-\text{NH}_2$	
$-\text{OH}$	$-\text{OCH}_3$, $-\text{OCH}_2\text{OCH}_3$, $-\text{OSi}(\text{CH}_3)_3$, $-\text{OSi-C(CH}_3)_3$ or $-\text{OCH}_2\text{phenyl}$

- 11 -

For preparing pharmaceutical compositions from the compounds described by this invention, inert, pharmaceutically acceptable carriers can be either solid or liquid. Solid form preparations include powders, tablets, dispersible granules, capsules, cachets and suppositories. The powders and tablets may be comprised of from about 5 to about 95 percent active ingredient. Suitable solid carriers are known in the art, e.g. magnesium carbonate, magnesium stearate, talc, sugar or lactose. Tablets, powders, cachets and capsules can be used as solid dosage forms suitable for oral administration. Examples of pharmaceutically acceptable carriers and methods of manufacture for various compositions may be found in A. Gennaro (ed.), Remington's Pharmaceutical Sciences, 18th Edition, (1990), Mack Publishing Co., Easton, Pennsylvania.

Liquid form preparations include solutions, suspensions and emulsions. As an example may be mentioned water or water-propylene glycol solutions for parenteral injection or addition of sweeteners and opacifiers for oral solutions, suspensions and emulsions. Liquid form preparations may also include solutions for intranasal administration.

Aerosol preparations suitable for inhalation may include solutions and solids in powder form, which may be in combination with a pharmaceutically acceptable carrier, such as an inert compressed gas, e.g. nitrogen.

Also included are solid form preparations which are intended to be converted, shortly before use, to liquid form preparations for either oral or parenteral administration. Such liquid forms include solutions, suspensions and emulsions.

The compounds of the invention may also be deliverable transdermally. The transdermal compositions can take the form of creams, lotions, aerosols and/or emulsions and can be included in a transdermal patch of the matrix or reservoir type as are conventional in the art for this purpose.

Preferably the compound is administered orally.

Preferably, the pharmaceutical preparation is in a unit dosage form. In such form, the preparation is subdivided into suitably sized unit doses containing appropriate quantities of the active component, e.g., an effective amount to achieve the desired purpose.

The quantity of active compound in a unit dose of preparation for treatment of asthma, cough, bronchospasm, inflammatory diseases, migraine, nociception, depression, emesis and gastrointestinal disorders

- 12 -


may be varied or adjusted from about 1 mg to about 1500 mg, preferably from about 50 mg to about 500 mg, more preferably from about 20 mg to about 200 mg, according to the particular application.

The actual dosage employed may be varied depending upon the requirements of the patient and the severity of the condition being treated. Determination of the proper dosage regimen for a particular situation is within the skill of the art. For convenience, the total daily dosage may be divided and administered in portions during the day as required.

The amount and frequency of administration of the compounds of the invention and/or the pharmaceutically acceptable salts thereof will be regulated according to the judgment of the attending clinician considering such factors as age, condition and size of the patient as well as severity of the symptoms being treated. A typical recommended daily dosage regimen for oral administration can range from about 1 mg/day to about 1500 mg/day, in two to four divided doses.


Following are examples of preparing starting materials and compounds of formula I. As used herein, Me is methyl, Bu is butyl, Br is bromo, Ac is acetyl, Et is ethyl and Ph is phenyl.

Preparation 1




Prepared using methods described in U.S. 5,696,267.

Preparation 2



25 Prepared using methods described in U.S. 5,696,267

Preparation 3



- 13 -


Step 1: Treat a solution of 1-benzyl-4-amino piperidine (25 g, 0.13 mol) in CH₃OH (5 mL) with acrylonitrile (9.6 mL, 0.15 mol) at 23 °C. Stir for 22 h, and concentrate to yield the crude product.

Step 2: Dissolve the product of Step 1 (31.9 g, 0.13 mol) in CH₃OH (1 L)

5 add cobalt (II) chloride (34 g, 0.26 mol) followed by NaBH₄ (50 g, 0.13 mol) in several small portion over 45 min at 0 °C. Allow the resulting suspension to stir for 1.5 h, carefully acidify with 3 N HCl until the color turns pink. Extract the aqueous solution with ether (Et₂O) (1 L), add NaOH at 10 °C until pH = 12. Extract the resulting suspension with Et₂O (1L), then CH₂Cl₂ (2 x 1L). Filter the aqueous layer to remove the solid material, and further extract with CH₂Cl₂ (3 x 1L). Concentrate the combined organic layer to give 23.6 g of the desired product.

Step 3: Dissolve the product of Step 2 (10.0 g, 0.41 mol) in anhydrous tetrahydrofuran (THF) (70 mL), treat with carbonyldiimidazole (13.2 g, 0.81 mol), and heat to 60 °C for 14 h. Concentrate the mixture, and filter through a silica plug with CH₂Cl₂ and CH₃OH (sat. with NH₃) at a ratio of 94:6 to give 8.6 g of the title product.

Preparation 4




20 Step 1: Treat a solution of 4-amino-N-benzyl piperidine (20.4 mL, 0.10 mol) in CHCl₃ (30 mL) with phthalide anhydride (10.0 g, 0.068 mol) and heat the mixture to reflux at 70 °C for 18 h. Add water and CH₂Cl₂, separate the layers, extract the aqueous layer with CH₂Cl₂ (2 x 40 mL), wash the combined organic layers with brine, concentrate and purify the mixture with column chromatography, eluting with CH₂Cl₂ and CH₃OH (sat. with NH₃) at a ratio of 99:1 to give 6.9 g of the desired product.

Step 2: Dissolve the product of Step 1 in acetic acid (HOAc) (10 mL), add zinc dust (1.28 g, 20 mmol) and heat to reflux at 120 °C for 12 h. After cooling the mixture, slowly add NaHCO₃ (sat.) solution until pH = 10,

30 separate the layers, extract the aqueous layer with CH₂Cl₂ (2 x 40 mL), wash the combined organic layers with brine, concentrate the mixture, and purify by column chromatography, eluting with EtOAc:hexane (1: 1) with 2% triethylamine (TEA) to give 0.50 g product.

- 14 -


Preparation 5



5 Treat a solution of 4-amino-N-benzyl piperidine (1.0 g, 5.26 mmol) and 2-acetylbenzoic acid (1.0 g, 6.10 mmol) in dichloroethane (10 mL) with NaBH₃CN (0.37 g, 6.0 mmol) and stir at 23 °C for 24 h. Heat the mixture to 80 °C for an additional 24 h. Add water (30 mL) and EtOAc (30 mL), filter through celite, separate layers of filtrate and concentrate the organic layer. Purify by column chromatography, eluting with EtOAc:hexane (1: 2) with 2% TEA to give 0.86 g product.

10


Preparation 6



Dissolve the product of Preparation 4, Step 1 (0.76 g, 2.38 mmol) in anhydrous THF (6 mL) and add CH₃MgBr (3 M, 2 mL, 6 mmol) at 0 °C.

15 Warm the mixture and stir at 23 °C for 3 h. Quench with water and CH₂Cl₂ at 0 °C, separate the layers, and extract the aqueous layer with CH₂Cl₂ (2 x 40 mL), wash the combined organic layer with brine and concentrate to give 0.68 g product.


Preparation 7



20 Using procedures known in the art, treat a solution of 3,4-dichlorophenylacetic acid with N-t-BOC-sarcosine methyl ester and separately treat 2-bromo-ethanol with t-butyldimethylsilylchloride. React the product of the first step with NaH, and add the product of the second step and NaI. Treat the resultant product with O-methoxylamine HCl, followed by deprotection using HCl in CH₂Cl₂. Chiral material was obtained by chiral separation using HPLC.

25

- 15 -



Step 1: Treat a solution of t-butyl-n-(2-aminoethyl)carbamate (18.6 g, 116 mmol) and 1-benzyl -4-piperidone (20 g, 106 mmol) in CH_2Cl_2 (300 mL) with HOAc (4.1 g, 68 mmol) and sodium triacetoxyborohydride (25 g, 118 mmol) at 0°C, and stir for an additional 15 h at 23°C. Add NaHCO_3 (sat.) (150 mL) and extract with CH_2Cl_2 (150 mL x 2), wash the combined organic layer with brine and concentrate to give 35.5 g product.

5 Step 2: Dissolve the product of Step 1 (7 g, 21 mmol) and Et_3N (6.37 g, 63 mmol) in CH_2Cl_2 (200 mL), add chloroacetyl chloride (2.85 g, 25 mmol), and stir for 2 h at 23°C. Add NaHCO_3 solution (150 mL) and extract with CH_2Cl_2 (150 mL x 2), wash the combined organic layer with brine and concentrate. Purify by column chromatography, eluting with CH_2Cl_2 and CH_3OH (sat. with NH_3) at a ratio of 97:3 to give 5.3 g product.

10 Step 3: Dissolve the product of Step 2 (5.3 g, 12.0 mmol) in CH_2Cl_2 with trifluoroacetic acid (15 mL) and stir for 1 h at 23°C. Remove the solvent under reduced pressure and dilute with CH_2Cl_2 and NaOH (1 M) until pH = 10. Extract with CH_2Cl_2 (150 mL x 2), wash the combined organic layer with brine, and concentrate to yield 3.3 g of the title compound.


15



20 Step 1: Use a procedure similar to Step 1 of Preparation 8, substituting glycine methyl ester hydrochloride for t-butyl-n-(2-aminoethyl)carbamate and HOAc.

25 Step 2: Treat the product of Step 1 with Boc-glycine using an amidation procedure similar to Step 1 of Example 7A.

Step 3: Treat the product of Step 2 with trifluoroacetic acid using a procedure similar to Step 3 of Preparation 8 to obtain the title compound.




- 16 -

Step 1: Dissolve 4-benzyl-piperidone (11.48 g, 50.7 mmol) in EtOH (60 mL), treat with 3-aminopropanol (8.29 g, 110.4 mmol) and stir for 90 min. Cool to 0°C and add HCl in dioxane (14 mL, 56 mmol), followed by NaBH₃CN (7.8 g, 124 nmol). Allow the mixture to warm up to 23°C, and

5 stir for additional 20 h. Quench with water and dilute with EtOAc, separate the organic layer and basify the aqueous layer until pH>10. Extract the organic layer with EtOAc (2 x 100 mL), wash the combined organic layer with brine and concentrate. Purify by column chromatography, eluting with CH₂Cl₂ and CH₃OH (sat. with NH₃) at a ratio of 94:6 to give 7.5 g product.

10 Step 2: Treat the product of step 1 using procedure similar to Preparation 3, Step 3, to give 6.6 g of the title compound.

Preparation 11



To a 5L 3-neck flask equipped with a mechanical stirring apparatus and charged with 1,2 dichloroethane (400 mL), add N-Boc-piperidone (20g, 100 mmol, 1 eq) followed by 3-amino-1-propanol (9.21 mL, 120 mmol, 1.2 eq) and stir for 30 min. Add Na(OAc)₃BH (25.4 g, 120 mmol, 1.2 eq) and stir for 4 h. Cool reaction to 0°C and add 300 mL of saturated aqueous NaHCO₃. Add p-nitrophenylchloroformate (30.25g, 150 mmol, 1.5 eq), stir

15 for 90 min and store for 14 h at -20°C. Warm to 0°C and check for complete reaction by TLC. Prepare a solution of NaBr (11.3 g, 110 mmol, 1.1 eq in 300 mL of saturated aqueous NaHCO₃ (sonicate for 5 min)) and add to the reaction vessel. Add TEMPO (156 mg, 1 mmol). With vigorous stirring, use a 500 mL addition funnel to add 300 mL of commercial bleach

20 (ca 0.7 M, 220 mmol, 2.2 eq). If reaction is not complete as shown by TLC, add bleach in small portions (25 mL) until complete. When TLC shows complete reaction, add saturated aqueous Na₂S₂O₃ (300 mL) and transfer to a separatory funnel. Isolate the organic layer and extract the aqueous layer with CH₂Cl₂ (2 x 1 L). Combine the organic layers and wash with

25 saturated aqueous NaHCO₃ (1 L). Back extract the last aqueous wash with 1 L CH₂Cl₂, dry over Na₂SO₄ and concentrate to give 65 g crude product. Purify by silica gel chromatography using 800 g silica, eluting with

30

- 17 -








hexane/EtOAc gradient elution (2:1 \rightarrow 1:1) to obtain 36.5 g (87%) of the desired aldehyde.

Preparations 12A-12O



Prep. no.	R ²⁶
12A	CH ₃
12B	(CH ₃) ₂ CH
12C	
12D	
12E	
12F	
12G	
12H	
12I	
12J	
12K	
12L	
12M	
12N	OH

- 18 -

12O	
12P	
12Q	
12R	
12S	
12T	
12U	

Preparation 12A

Step 1: Using a procedure similar to Preparation 11 with phenyl chloroformate in place of 4-nitrophenylchloroformate, prepare the corresponding phenyl carbamate aldehyde.

5 Step 2: Stir a solution of the product of step 1 (5 g, 13.2 mmol), NH_2CH_3 (7.3 mL of 2M in THF), in 2,2,2-trifluoroethanol (150 mL) for 30 min, then add 4.67 g of $\text{Na}(\text{OAc})_3\text{BH}$ and stir for 18h. Filter through a frit, rinse with EtOAc , wash the filtrate with sat NaHCO_3 then brine, dry with Na_2SO_4 and concentrate in vacuo. Dissolve the crude in DMF (100 mL) and heat to

10 100 °C for 1 h. Remove the DMF in vacuo and purify by silica gel chromatography, eluting with $\text{EtOAc}/\text{CH}_3\text{OH}$ 9:1 to obtain 2.46 g of the desired boc-piperidine.

15 Step 3: Dissolve the product of step 2 in 30 mL of CH_2Cl_2 (30 mL) at 0°C and treat with 50 mL of HCl/dioxane (4N) and stir until no starting material remains by TLC. Concentrate in vacuo and filter the resulting HCl salt through a plug of silica gel, eluting with $\text{CH}_2\text{Cl}_2/\text{CH}_3\text{OH}$ (sat with NH_3) to obtain the desired piperidine free base.

Preparation 12B

20 Using a procedure similar to Preparation 12A, substitute isopropylamine for NH_2CH_3 and heat to 125°C for 6-8h instead of 100 °C for 1h in step 2.

Preparation 12C-12H

Step 1: Using a procedure similar to that of Preparation 12A, substituting the product of Preparation 11 for the phenyl carbamate in step 1 and using the appropriate amine, the corresponding Boc-piperidines were prepared.

5 For insoluble amines (Prep. 12D) 1-20% Et₃N was added to 2,2,2 trifluoroethanol as a co-solvent in step 2. In step 2, hindered amines (Prep. 12H) may require sustained heating (120 °C, 4-5d) in DMF for cyclization to occur. For less hindered amines, cyclization may be spontaneous and may not require heating in DMF.

10 Step 2: Deprotect, using a procedure similar to Preparation 12A, step 3.

Preparation 12I-12L

Treat a solution (0.05-0.25 mmol) of the desired Boc protected piperidine obtained from Preparation 12E-12H, step 1, in CH₂Cl₂ with 1.5-5 eq mCPBA and stir for 2-18 h. Concentrate in vacuo and purify by silica gel chromatography. Deprotect the Boc group using a procedure similar to that of Preparation 12A, step 3, to give the appropriate piperidine.

Preparation 12M

Using a procedure similar to Preparations 12C-H, steps 1 and 2, substituting glycineamide for the appropriate amine, the resulting 20 glycineamide substituted urea / piperidine free base is prepared.

Preparation 12N

Step 1: Treat a solution of the product of Preparation 12A, step 1 (6.2 g, 16.5 mmol) in pyridine (100 mL) with NH₂OH (1.72 g, 24.7 mmol) and heat to 60°C for 2.5 h. Cool and concentrate in vacuo and purify by silica gel chromatography, eluting with CH₂Cl₂/CH₃OH (NH₃) to obtain 5.9 g (88%) of the oxime as a white powder.

Step 2: Treat a solution of the product of step 1 (5.7 g, 15 mmol) in 170 mL CH₃OH with a trace amount of methyl orange indicator followed by NaCNBH₃ (1.03 g). Add 1M HCl/CH₃OH until mixture remains orange (ca. 30 23 mL). Quench with 400 mL EtOAc and 75 mL sat NaHCO₃. Filter the resulting emulsion through celite and wash with EtOAc. Wash organic layers with 75 mL saturated NaHCO₃, then brine, dry over Na₂SO₄ and concentrate in vacuo to obtain 3.82 g (67%) of the hydroxyl amine as a colorless glass.

35 Step 3: Dissolve the product of step 2 in 50 mL DMF and heat to 100 °C for 4 h. Concentrate in vacuo and purify by silica gel chromatography using CH₂Cl₂/ CH₃OH (NH₃) to obtain 3.0g (99%) of the hydroxyl urea.

- 20 -

Step 4: In a procedure similar to Preparation 12A, step 3, deprotect the Boc group to obtain the desired piperidine.

Preparation 12O

Step 1: Treat a solution of the product of Preparation 12A, step 1 (3.0 g, 5 7.13 mmol) in 1,2-dichloroethane (20 mL) with aminomorpholine (1.37 mL, 14.25 mmol) and Na(OAc)₃BH (3.0g). Isolate the resulting hydrazone by filtering the reaction mixture through a frit and concentrating in vacuo.

Step 2: Treat a solution of the product of step 1 in 50 mL THF with 1 eq of 10 tosic acid followed by NaCNBH₃ (2 eq). Quench with sat. NaHCO₃ and extract with EtOAc. Wash the organic layers with saturated NaHCO₃, then brine, dry over Na₂SO₄ and concentrate in vacuo. Purify by silica gel chromatography, eluting with EtOAc/hexane (2:1) with 2% Et₃N to obtain 1.5 g of the desired hydrazone.

Step 3: Dissolve the product of step 2 in 50 mL DMF and heat to 120 °C 15 for 3 h. Concentrate in vacuo and purify by silica gel chromatography, eluting with CH₂Cl₂/CH₃OH (NH₃) to obtain 255 mg (10 %, 2 steps) of the aminomorpholino urea.

Step 4: In a procedure similar to Preparation 12A, step 3, deprotect the 20 Boc group to obtain the desired piperidine.

Preparation 12P

Step 1: Using a procedure similar to Preparation 12A, Step 2, substitute 25 aminoacetonitrile for methyl amine. Dissolve the product in CH₃OH, add Raney Ni, and shake the resulting mixture on a Parr shaker at 50 psi of H₂ pressure for 3 h. Filter the mixture through celite and concentrate to give the desired product.

Step 2: Dissolve the product of Step 1 (0.17 g, 0.52 mmol) in CH₂Cl₂ and 30 treat with methyl isocyanate (0.035 ml, 0.57 mmol) at 23 °C for 3 h. Dilute with water and CH₂Cl₂, separate the layers, and extract the aqueous layer with CH₂Cl₂ (2 x 40 ml), wash the combined organic layers with brine and concentrate. Purify by column chromatography using CH₂Cl₂ and CH₃OH (sat. with ammonia) at a ratio of 98:2 to give 0.68 g of product.

Step 3: Use a procedure similar to Preparation 12A, Step 3, to give the 35 desired product.

Preparation 12Q-12T

Using a procedure similar to Preparation 12B, substitute for methyl 35 isocyanate the appropriate isocyanate or chloride.

Preparation 12U

Step 1: Dissolve the product form Preparation 12P, Step 1, in dioxane,


- 21 -

treat with sulfamide, reflux at 100 °C for 8 h, and concentrate to give a crude product.

Step 2: Use a procedure similar to Preparation 12A, Step 3, to give the desired product.

5

EXAMPLE 1



Step 1: Dissolve product of Preparation 3 (11.3 g, 0.042 mol) in anhydrous dimethylformamide (DMF) (30 mL), treat it with lithium

10 bis(trimethylsilyl)amide (1 M, 50 mL, 0.050 mol) at 0 °C, allow the reaction mixture to warm up to 23 °C over 40 min. Add t-butyl bromoacetate (13.5 mL, 0.084 mol), and stir for 18 h. Quench with water and dilute with ethyl acetate (EtOAc), separate the organic layer, concentrate and purify the mixture by column chromatography eluting with CH₂Cl₂ and CH₃OH (sat. with NH₃) at a ratio of 98:2 to give 12.1 g product.

Step 2: Bubble HCl into a solution of the product of Step 1 (12.2 g, 0.032 mol) in CH₃OH (200 mL) for 15 min at 0 °C and heat the resulting solution at 60 °C for 2 h. After cooling, pour the reaction mixture into 10% aqueous NaOH solution (100 mL) and add NaHCO₃ solution (sat.) until pH = 10.

20 Separate the organic layer and further extract the aqueous layer with CH₂Cl₂ (2 x 100 mL), wash the combined organic layer with brine and concentrate to yield 12.3 g product.

Step 3A: Dissolve the product of Step 2 (1 g, 3.0 mmol) in CH₃OH (10 mL) add Pd(OH)₂ on carbon (150 mg), and shake the resulting mixture on a

25 Parr shaker at 50 psi of H₂ pressure for 3 h. Filter the mixture through celite and concentrate to give a crude product. Re-dissolve the product and the aldehyde from Preparation 1 (1.5 g, 3.14 mmol) in trifluoroethanol (10 mL), treat with 3 Å molecular sieves (0.3 g) and NaBH₃CN (0.37 g, 6.0 mmol), and stir for 2 h. Add water (30 mL) and EtOAc (30 mL), filter the

30 mixture through celite, separate layers of filtrate, extract the aqueous solution with EtOAc (2 x 40 mL), and concentrate the combined organic layer. Purify by column chromatography, eluting with CH₂Cl₂ and CH₃OH


- 22 -

(sat. with NH₃) at a ratio of 98:2 to give 0.89 g of desired product. HRMS (FAB, M+H⁺): Calc'd: 714.1784, found: 714.1791.

Step 3B: Alternatively, to prepare optically active material, proceed in a similar manner as Step 3A using the aldehyde from Preparation 2 in place of the aldehyde from Preparation 1, dichloroethane in place of trifluoroethanol, and sodium triacetoxyborohydride in place of NaBH₃CN.

5 HRMS (FAB, M+H⁺): Calc'd: 714.1784, found: 714.1779.

EXAMPLE 2




10 Step 1: Using a procedure similar to Preparations 12C-H, steps 1 and 2, and substituting serine methyl ester• HCl for the appropriate amine, the resulting serine methyl ester substituted urea / piperidine free base is prepared.

15 Step 2: Treat the product of step 1 (3.68 mmol) in 1,2 dichloroethane (20 mL and 5 mL CF₃CH₂OH) with Preparation 2 (1.23 g, 2.45 mmol) and 3Å MS (1.5g). Stir for 30 min, then add Na(OAc)₃BH (943 mg, 4.5 mmol) and stir for 1-5 h. Filter through celite and wash the celite pad with EtOAc. Transfer to a separatory funnel and wash with sat NaHCO₃ (2 x 50 mL) then brine, dry the organic layer with Na₂SO₄ and concentrate in vacuo.

20 Purify by chromatography (EtOAc/NEt₃) to obtain 1.3 g of the desired product.


EXAMPLE 3



25 Use a procedure similar to Example 2, substituting tyrosine ethyl ester• HCl for serine methyl ester• HCl to obtain the product.

- 23 -

EXAMPLE 4



Ex.	R ²⁶	HRMS (FAB, M+H ⁺)
4A		Calc'd: 700.1627, found: 700.1619
4B		Calc'd: 753.2256 found: 753.2248
4C		Calc'd: 727.2100, found: 727.2120
4D		Calc'd: 713.1943, found: 713.1937
4E		Calc'd: 699.1787, found: 699.1784
4F		Calc'd: 769.2206, found: 769.2207
4G		Calc'd: 782.2522, found: 782.2514
4H		n=1 Calc'd: 785.1977, found: 785.1974 n=2 Calc'd: 817.1875, found: 817.1862
4I		Calc'd: 782.1617 found: 782.1624
4J		Calc'd: 783.1569 found: 783.1570

- 24 -

4K		Calc'd: 728.1940. found: 728.1930
4L		Calc'd: 782.1657 found: 782.1662
4M		Calc'd: 771.2362 found: 771.2350
4N		Calc'd: 790.2097 found: 790.2103
4O		Calc'd: 740.1940 found: 740.1943
4P		Calc'd: 742.2097 found: 742.2091
4Q		Calc'd: 768.2253 found: 768.2235
4R		Calc'd: 784.2202 found: 784.2198
4S		Calc'd: 758.1868 found: 782.1862
4T		Calc'd: 806.1868 found: 806.1853
4U		Calc'd: 784.2025 found: 784.2022
4V		Calc'd: 728.1940, found: 728.1932
4W		Calc'd: 714.1784, found: 714.1776
4X		Calc'd: 741.2256, found: 741.2247

- 25 -

4Y		Calc'd: 686.1834 found: 686.1855
4Z		Calc'd: 700.1991 found: 700.1984
4ZZ		Calc'd: 776.2304 found: 776.2302

Example 4A:

Dissolve the product of Step 3A of Example 1 (0.50 g, 0.69 mmol) in CH₃OH (6 mL), add a solution of NaOH (60 mg, 1.5 mmol) in water (0.25 mL), and stir for 4 h. Add an equivalent of HCl (10% in water) and extract the mixture with 15% CH₃OH in CH₂Cl₂ (5 x 30 mL). Concentrate the combined organic layer and purify by column chromatography using 15% CH₃OH in CH₂Cl₂ to give 0.36 g of the desired product.

Example 4B:

Dissolve the product of Example 4A (60 mg, 0.086 mmol) and carbonyldiimidazole (28 mg, 0.17 mmol) in CH₂Cl₂ (1 mL), and add pyrrolidine (22 mL, 0.26 mmol) at 0°C. After stirring at 23°C for 12 h, add water (20 mL) and CH₂Cl₂ (20 mL), separate the layers, extract the aqueous layer with CH₂Cl₂ (2 x 20 mL), wash the combined organic layer with brine, concentrate, and purify the mixture with column chromatography eluting with CH₂Cl₂ and CH₃OH with NH₃ (98:2) to give 47 mg of the product.

Examples 4C - 4J:

Prepare the compounds by reacting the product of Example 4A with an appropriate amine according to procedure similar to Example 4B.

Example 4K:

Dissolve the product of Example 4A (200 mg, 0.29 mmol), 1,3-dicyclohexylcarbodiimide (DCC) (87 mg, 0.43 mmol) and 4-dimethylaminopyridine (DMAP) (53 mg, 0.43 mmol) in CH₂Cl₂ (2 mL), add EtOH (25 mL, 0.43 mmol) at 0°C. After stirring at 23°C for 12 h, add water (20 mL) and CH₂Cl₂ (20 mL), separate the layers, extract the aqueous layer with CH₂Cl₂ (2 x 20 mL), wash the combined organic layer with brine, concentrate and purify the mixture with column chromatography eluting with CH₂Cl₂ and CH₃OH with NH₃ (97:3) to give 165 mg of the product.

- 26 -

Examples 4L - 4R:

Prepare the target compounds by reacting the product of Example 4A with an appropriate alcohol according to a procedure similar to Example 4K.

5 Example 4S - 4T:

Prepare the compounds using a procedure similar to Example 4K, using bis(2-oxo-3-oxazolidinyl)phosphinic chloride (BOP-Cl), Et₃N and appropriate thiols in place of DCC, DMAP and EtOH.

Example 4V:

10 Use a procedure similar to Example 1, Step 1, using methyl 3-bromopropionate in place of t-butyl bromoacetate, followed by debenzylation and reductive amination using a procedure similar to Example 1, Step 3.

Example 4W:

15 Treat the product of Example 4Y using a hydrolysis procedure similar to that of Example 4A.

Example 4X:

Treat the product of Example 4W using an amidation procedure similar to Example 4B using (CH₃)₂NH in place of pyrrolidine.

20 Example 4Y:

1) Dissolve the product of Preparation 11 (19 g, 44 mmol) and ethanolamine (4 mL, 66 mmol) in dichloroethane (120 mL) and stir for 30 min. Treat with sodium triacetoxyborohydride (14 g, 66 mmol) and stir for 14 h. Add NaHCO₃ (sat.) (150 mL), extract with CH₂Cl₂ (150 mL x 2), wash the combined organic layer with brine and concentrate to give 8.75 g product.

25 2) Treat the product of Step 1 by a procedure similar to Example 1, Step 3A, to give the product.

Example 4Z:

30 Dissolve the product of Example 4Y (138 mg, 0.2 mmol) in dry THF (1 mL), add NaH (16 mg, 0.4 mmol) at 0°C and stir for 15 min. Add CH₃I (19 mL, 0.3 mmol) at 0°C, allow the mixture to warm to 23°C, and stir for 2 h. Quench the reaction at 0°C with water (10 mL) and dilute with EtOAc (10 mL). Separate the layers, extract aqueous solution with EtOAc (2 x 40 mL) and concentrate the combined organic layer. Purify by column chromatography using EtOAc and CH₃OH (99:1) with 5% Et₃N to give 103 mg product.

- 27 -

Example 4ZZ:

Treat the product of Example 4Y using a procedure similar to Example 4Z substituting benzyl bromide for CH_3I .

EXAMPLE 5




5

Ex.	Z	HRMS (FAB, $\text{M}+\text{H}^+$)
5A		Calc'd: 675.1463, found: 675.1459
5B		Calc'd: 689.1620, found: 689.1618
5C		Calc'd: 705.1569, found: 705.1565

Example 5A-5C

Prepare the compounds by a procedure similar to Example 1, Step 3, using the products of Preparations 4, 5 and 6, respectively.

EXAMPLE 6

















10

Ex.	R^{26}	HRMS (FAB, $\text{M}+\text{H}^+$) (unless otherwise specified)
6A		Calc'd: 700.1627, found: 700.1619
6B		Calc'd: 753.2256, found: 753.2254
6C		Calc'd: 727.2100, found: 727.2105

- 28 -

6D		Calc'd: 713.1943, found: 713.1941
6E		Calc'd: 769.2206, found: 769.2204
6F		Calc'd: 699.1791, found: 699.1787
6G		Calc'd: 785.1977, found: 785.1987
6H		Calc'd: 728.1940 found: 728.1942
6I		Calc'd: 686.1834 found: 686.1846
6J		Calc'd: 716.1754 found: 716.1744
6K		Calc'd: 714.2147 found: 714.2143
6L		Calc'd: 742.2097 found: 742.2081
6M		Calc'd: 728.1940 found: 728.1930
6N		Calc'd: 729.2070 found: 785.2061
6O	H	Calc'd: 642.1572, found: 642.1570
6P	CH ₃	LRMS: (M+H ⁺) 657.9
6Q	(CH ₃) ₂ CH-	LRMS: (M+H ⁺) 687.0
6R		Calc'd: 722.1834, found: 722.1832

- 29 -

6S		Calc'd: 724.1852, found: 724.1879
6T		LRMS: (M+H ⁺) 735.2
6U		LRMS: (M+H ⁺) 735.2
6V		LRMS: (M+H ⁺) 735.2
6W		Calc'd: 719.1838, found: 719.1849
6X		LRMS: (M+H ⁺) 751.2
6Y		Calc'd: 749.1943, found: 749.1922
6Z		Calc'd: 749.1943, found: 749.1937
6AA		Calc'd: 735.1787, found: 735.1800
6BB		Calc'd: 730.1733, found: 730.1733
6CC		Calc'd: 806.2046, found: 806.2034
6DD		LRMS: (M+H ⁺) 731.1
6EE		LRMS: (M+H ⁺) 807.2
6FF		Calc'd: 699.1787, found: 699.1791

- 30 -

6GG		Calc'd: 714.1898, found: 714.1891
6HH		Calc'd: 698.1967, found: 698.1959
6II	OH	Calc'd: 660.1492, found: 660.1487
6JJ		LRMS: (M+H ⁺) 660.2
6KK		LRMS: (M+H ⁺) 717.2
6LL		Calc'd: 727.2100, found: 727.2114
6MM		Calc'd: 742.2209, found: 742.2199
6NN		LRMS: (M+H ⁺) 730
6OO		LRMS: (M+H ⁺) 800
6PP		Calc'd: 729.2070, found: 729.2052
6QQ		Calc'd: 765.1740, found: 765.1747
6RR		Calc'd: 766.1693, found: 766.1685

Example 6A:

Prepare the compound by a procedure similar to Example 4A using product of Example 1, Step 3B in place of the product of Example 1, Step 3A.

5 Example 6B-6G:

Treat the product of Example 6A with appropriate amines using an amidation procedure similar to Example 4B using 1-(3-dimethylamino-

- 31 -

propyl-3-ethylcarbodiimide (EDC) and 1-hydroxybenzotriazole (HOBt) in place of carbonyldiimidazole.

Example 6H-6J:

5 Prepare the compounds by procedures similar to Examples 4K, 4Y and 4W, except using the optically pure product from Preparation 2 in place of product of Preparation 1.

Example 6K:

10 Dissolve the product of Example 6H (0.12 g, 0.16 mmol) in anhydrous THF (2 mL) and add CH_3MgBr (3 M, 0.2 mL, 0.6 mmol) at 0°C. Warm the mixture and stir at 23°C for 3 h. Add water and CH_2Cl_2 at 0°C, separate the layers, extract the aqueous layer with CH_2Cl_2 (2 x 40 mL), wash the combined organic layer with brine and concentrate. Purify by column chromatography eluting with CH_2Cl_2 and CH_3OH (99:1 to 95:5) to give 0.05 g of the product.

15 Example 6L:

Step 1: Use the procedure in Preparation 11, substituting N-benzyl piperidone for N-Boc-piperidone, and substituting a standard Swern oxidation for TEMPO oxidation.

20 Step 2: Dissolve the product of Step 1 (6.83 g, 16.6 mmol) and α,α -dimethyl glycine methyl ester hydrochloride (2.86 g, 18.6 mmol) in trifluoroethanol (32 mL) and CH_2Cl_2 (63 mL), add NaSO_4 (2.8 g) and stir for 30 min. Treat the mixture with sodium triacetoxy borohydride and stir for additional 4 h. Filter off the solid and concentrate to yield the crude product. Purify by column chromatography eluting with EtOAc and CH_3OH (99:1 to 95:5) to give 7.65 g product.

25 Step 3: Dissolve the product of Step 2 (1.54 g, 3 mmol) in toluene (140 mL) and heat in a sealed tube at 120°C for 40 h. Cool and remove the solvent, re-dissolve in EtOAc and CH_2Cl_2 , wash with 1 N NaOH , brine and concentrate to yield 0.97 g product.

30 Step 4: Treat the product in Step 3 using a procedure similar to Preparation 3, Step 3, to give the product.

Example 6M:

Step 1: Treat the product of Step 3 of Example 6L with a hydrolysis procedure similar to Example 6A, but reflux at 70°C for 24 h.

35 Step 2: Treat the product of Step 1 using a procedure similar to Example 1, Step 3 to give the product.

- 32 -

Example 6N:

Treat the product of Example 6M with an amidation procedure similar to Example 4E to give the product.

Example 6O:

5 Step 1: Dissolve the product of Preparation 3, step 3 (2.0g, 7.5 mmol) in CH₃OH (50 mL) and treat with Pd(OH)₂ (20% on C, 50% H₂O) followed by H₂ (40 psi). After shaking for 17 h on Parr shaker, filter through celite and concentrate to obtain the desired piperidine (1.33 g, 7.3 mmol, 98%).

10 Step 2: Treat the product of step 1 (2.13g, 4.5 mmol) in 1,2-dichloroethane (15 mL) with Preparation 2 (1.42 g, 3.0 mmol) and 3ÅMS (2g). Stir for 30 min and then add Na(OAc)₃BH (943 mg, 4.5 mmol) and stir for 1-5 h. Filter through celite and wash the celite pad with EtOAc. Transfer to a separatory funnel, wash with sat NaHCO₃ (2 x 50 mL), brine and dry the organic layer with Na₂SO₄ and concentrate in vacuo. Purify by

15 chromatography (EtOAc/NEt₃ --> EtOAc/NEt₃/CH₃OH gradient) to obtain 810 mg of the desired product.

Example 6P through 6AA, 6FF, 6II, and 6LL-6RR:

Use the appropriate piperidine from Preparation 12A through 12L, 12M, 12N, and 12O-12U and the aldehyde from Preparation 2 in a procedure similar to example 6O, step 2 to obtain the title compounds.

Example 6BB:

Use the product of Example 2 in a procedure similar to Example 4A to obtain the corresponding carboxylic acid compound.

Example 6CC:

25 Use the product of Example 3 in a procedure similar to Example 4A substituting LiOH for NaOH and aqueous DME for CH₃OH to obtain the corresponding carboxylic acid title compound.

Examples 6DD and 6EE:

30 With Examples 6BB and 6CC as the starting carboxylic acids, use a procedure similar to Example 4K using HOBT in place of DMAP and using NH₃ in THF as the amine to obtain Examples 6DD and 6EE, respectively.

Example 6GG:

35 Step 1: Cool a suspension of dry NH₄Cl (58 mg) in benzene (5 mL) to 0°C and treat with 525 µL of 2M trimethylaluminum in toluene. Warm to 23°C and stir for 1 h. Add 250 mg of example 6FF and heat the mixture to reflux for 2.5 h. Cool and remove the solvent in vacuo and purify the resulting nitrile by silica gel chromatography using CH₂Cl₂/CH₃OH (NH₃) (95:5) as the eluant to obtain 140 mg (57%) of the nitrile.

- 33 -

Step 2: Sonicate a mixture of NH₂OH (152 mg, 2.21 mmol) in dry EtOH (5 mL) and 1N KOH/CH₃OH (1.76 mL) for 15 min. Add this suspension to a solution of the product of step 1 (300 mg) in dry EtOH (7 mL) with 3ÅMS and heat to reflux for 2 h. Quench with saturated NaHCO₃, dilute with

5 EtOAc (150 mL), filter through a frit and concentrate in vacuo. Purify by silica gel chromatography using CH₂Cl₂/CH₃OH (NH₃) (97:3 -->95:5) to obtain the title compound.

Example 6HH:

Treat a solution of the product of Example 6GG, step 1 (300 mg) in

10 CH₃OH (5 mL) with 47 mg of NaOCH₃ and stir for 18 h at 23°C. Add dry NH₄Cl and stir for 4 h. Remove the solvent in vacuo and purify by silica gel chromatography using CH₂Cl₂/CH₃OH (NH₃) (95:5 -->80:10) to obtain 262 mg (86%) of the title compound.

Example 6JJ:

15 Treat a solution of example 6II (250 mg, 0.38 mol) and 46 µL (0.57 mmol) of pyridine in 3 mL CH₂Cl₂ with methylisocyanate (33.5 µL, 0.57 mmol) and stir for 3 h. Remove the solvent in vacuo and purify by silica gel chromatography using CH₂Cl₂/CH₃OH (NH₃) (95:5) to obtain 226 mg (83%) of the title compound.

20 Example 6KK:


Step 1: Treat a solution of Example 6II (500 mg, 0.76 mol) in dry DMF (10 mL) at 0°C with NaH (46 mg, 60%) and stir for 30 min. Add methylbromoacetate (86 µL, 0.914 mmol) stir for 30 min and quench with 3 mL saturated NaHCO₃. Extract with EtOAC, filter through a frit, wash with

25 saturated NaHCO₃, brine, dry with Na₂SO₄ and concentrate in vacuo. Purify by silica gel chromatography using CH₂Cl₂/CH₃OH (NH₃) (97:3) to obtain 440 mg (79%) of the methyl ester.

Step 2: Treat a solution of the product of step 1 (389 mg) with CH₃OH saturated with NH₃ (20 mL) and sonicate for 2 h. Concentrate in vacuo.

30 Purify by silica gel chromatography using CH₂Cl₂/CH₃OH (NH₃) (95:5) to obtain 300 mg (79%) of the title compound.

EXAMPLE 7



Ex.	E	HRMS (FAB, M+H ⁺)
7A		Calc'd: 602.2665 found: 602.2674
7B		Calc'd: 610.2163 found: 610.2181
7C		Calc'd: 639.2020 found: 639.2006
7D		Calc'd: 710.2116 found: 710.2099
7E		Calc'd: 642.2226 found: 642.2226
7F		Calc'd: 618.2272 found: 618.2264

Example 7A:

Step 1: Dissolve the product of Preparation 7 (1.0 g, 1.36 mmol), EDC (.38 g, 2.00 mmol) and HOBr (0.24 g, 1.8 mmol) in CH₂Cl₂ (5 mL), add 3,5-dimethyl benzoic acid (0.3 g, 2.00 mmol) and Et₃N (.7 mL, 4.00 mmol) at 5 0°C. After stirring at 23°C for 12 h, add water (20 mL) and CH₂Cl₂ (20 mL), separate the layers, extract the aqueous layer with CH₂Cl₂ (2 x 20 mL), wash the combined organic layer with brine, concentrate and purify the mixture with column chromatography using CH₂Cl₂ and CH₃OH with NH₃ (98:2) to give 0.22 g product.

10 Step 2: Dissolve the product of Step 1 (0.22 g, 0.25 mmol) in dry THF (2 mL), treat the solution with tetrabutylammonium fluoride (1M, 0.3 mL, 0.30 mmol) at 0°C. Allow the mixture to warm up to 23°C over 30 min and stir additional 1 h. Dilute with EtOAc (50 mL) and water (50 mL), extract aqueous phase with EtOAc (2 x 40 mL) and concentrate the combined 15 organic layer. Purify by column chromatography using EtOAc and hexane (1:1) to obtain 0.15 g product.

Step 3: Dissolve the product of Step 2 (140 mg, 0.32 mmol) in EtOAc (3 mL), prepare a solution of NaBr (33 mg, 0.32 mmol) in 3 mL of saturated

- 35 -


aqueous NaHCO₃, and add to the reaction vessel. Add TEMPO (1 mg). With vigorous stirring, add 1 mL of commercial bleach (ca 0.7 M, 0.7 mmol). Add saturated aqueous Na₂S₂O₃ (3 mL), isolate the organic layer and extract the aqueous layer with CH₂Cl₂. Combine the organic layers, 5 wash with saturated aqueous NaHCO₃, and concentrate to give 140 mg aldehyde as the product.

Step 4: Hydrogenate the product of Preparation 3 using a procedure similar to that described in Example 1, Step 3. React the resulting deprotected product with the aldehyde from Step 3 in a similar procedure 10 to that described in Example 1, Step 3, to yield the title product.

Example 7B-7F:






Prepare the compounds by a procedure similar to Example 7A using appropriate aryl acids.

EXAMPLE 8



15

Ex.	R ²⁹	HRMS (FAB, M+H ⁺)
8A	H—	Calc'd: 642.1572 found: 642.1555
8B	Me—	Calc'd: 656.1729 found: 656.1714
8C	—C(=O)CH ₂ —	Calc'd: 684.1678 found: 684.1660
8D	—C(=O)CH ₂ —Ph	Calc'd: 746.1834 found: 746.1837
8E	—C(=O)CH ₂ CH ₂ —	Calc'd: 742.1733 found: 742.1734
8F	—C(=O)CH ₂ —NH—	LRMS 699 (M+1)
8G	—C(=O)CH ₂ CH ₂ CH ₂ —	Calc'd: 728.1940 found: 728.1934

8H		Calc'd: 714.1784 found: 714.1788
8I		Calc'd: 713.1943 found: 713.1944
8J		Calc'd: 701.1757 found: 701.1767
8K		Calc'd: 734.1504 found: 734.1523
8L		Calc'd: 721.1300 found: 721.1308

Example 8A:

Step 1: Treat the product of Preparation 8 (240 mg, 0.88 mmol) in CH_2Cl_2

(3 mL) with 2-(trimethylsilyl)ethyl 4-nitrophenyl carbonate (350 mg, 1.24 mmol), and stir for 14 h. Add water and CH_2Cl_2 , and extract the aqueous

5 layer with CH_2Cl_2 (2 x 20 mL), wash the combined organic layer with brine, concentrate and purify the mixture with column chromatography using CH_2Cl_2 and CH_3OH with NH_3 (98:2) to give 149 mg product.

Step 2: Treat the product of Step 1 using a procedure similar to Step 3A of Example 1. Alternatively, for optically pure product, use a procedure similar

10 to Step 3B of Example 1.

Step 3: Treat the product of Step 2 (190 mg, 0.24 mmol) in THF (2 mL) with tetrabutylammonium fluoride (1M, 0.5 mL, 0.50 mmol), and stir for 3 h. Add water and CH_2Cl_2 , and extract the aqueous layer with CH_2Cl_2 (2 x 20 mL), wash the combined organic layer with brine, concentrate and purify the

15 mixture with column chromatography using CH_2Cl_2 and CH_3OH with NH_3 (95:5) to give 119 mg of the title product.

Example 8B:

Step 1: Treat the product of Preparation 8 (320 mg, 1.17 mmol) in THF (3 mL) with NaH (60% in mineral oil, 56 mg, 1.41 mmol) at 0°C for 15 min,

20 and add CH_3I (88 mL, 1.41 mmol). After stirring for 2 h, quench with water and CH_2Cl_2 , extract the aqueous layer with CH_2Cl_2 (2 x 20 mL), wash the combined organic layer with brine, concentrate and purify the mixture with column chromatography using CH_2Cl_2 and CH_3OH with NH_3 (95 :5) to give 180 mg product.

25 Step 2: Treat the product of Step 1 using a procedure similar to Step 3B of Example 1 to give the title compound.

- 37 -

Example 8C:

Step 1: Treat the product of Preparation 8 (250 mg, 0.92 mmol) in CH₂Cl₂ (3 mL) with ET₃N and acetyl chloride (90 mg, 1.19 mmol), and stir for 2 h. Add water and CH₂Cl₂, extract the aqueous layer with CH₂Cl₂ (2 x 20 mL), 5 wash the combined organic layer with brine, concentrate and purify the mixture with column chromatography using CH₂Cl₂ and CH₃OH with NH₃ (95 :5) to give 230 mg product.

Step 2: Treat the product of Step 1 using a procedure similar to Step 3 of Example 1 to give the title compound.

10 Examples 8D-F and 8K:

Prepare the desired compounds by a procedure similar to that described in Example 8C using appropriate the acyl halide, isocyanate or sulfonyl chloride.

Examples 8G and 8H:

15 Prepare the desired compounds by a procedure similar to that described in example 8B using appropriate alkyl halides.


Examples 8I and 8J:

Prepare the target compounds by stirring a mixture of NH₄OH and NH₄Cl with the products Examples 8G and 8H in CH₃OH for 48 h.

20 Example 8L:

Treat the product of Preparation 8 (250 mg, 0.92 mmol) in 1,4-dioxane (39 mL) with sulfamide (0.6 g, 6.3 mmol), and reflux for 24 h at 80°C. Concentrate and purify the mixture with column chromatography using CH₂Cl₂ and CH₃OH with NH₃ (95 :5) to give 150 mg of the title 25 product.

EXAMPLE 9



Ex.	R ²⁹	HRMS (FAB, M+H ⁺)
9A	H—{	Calc'd: 656.1365 found: 656.1357
9B	Me—{	Calc'd: 670.1521 found: 670.1514

- 38 -

9C		Calc'd: 728.1576 found: 728.1571
9D		Calc'd: 714.1420 found: 714.1438
9E		Calc'd: 769.1842 found: 769.1838
9F		Calc'd: 713.1580 found: 713.1569

Example 9A:

Treat the product of Preparation 9 using a procedure similar to Step 3A of Example 1. Alternatively, prepare the optically pure compound using a procedure similar to Example 1, Step 3B.

5 Example 9B:

Treat the product of Preparation 9 using a procedure similar to Example 8B to give the target compound.

Example 9C:

Treat the product of Preparation 9 using a procedure similar to Example 8H to give the title compound.


Example 9D:

Hydrolyze the product of Example 9C using a procedure similar to that described in Example 4A.

Examples 9E - 9G:







15 Acylate the product of Example 9D using a procedure similar to that described in Example 6G with appropriate amines.

EXAMPLE 10



Ex.	R ²⁹	HRMS (FAB, M+H ⁺)
10A		*LRMS: 730.1 (M+1)
10B		Calc'd: 714.1420 found: 714.1438

- 39 -

10C		Calc'd: 769.1842 found: 769.1848
10D		Calc'd: 713.1580 found: 713.1593
10E		Calc'd: 727.1736 found: 727.1733
10F		Calc'd: 741.1893 found: 741.1882
10G		Calc'd: 799.1770 found: 799.1767
10H		Calc'd: 783.1998 found: 783.2006
10I		Calc'd: 767.2049 found: 767.2054


Example 10A:





Prepare title compound by a procedure similar to Preparation 9 using L-N-Boc-aspartic acid methyl ester in place of glycine methyl ester.

Examples 10B -10I:

5 Prepare the desired compounds by standard hydrolysis and acylation procedures similar to those described in Examples 9D-9G.

EXAMPLE 11



Ex.	R ²⁹	HRMS (FAB, M+H ⁺)
11A		Calc'd: 713.1580 found: 713.1593
11B		Calc'd: 783.1998 found: 783.2012
11C		Calc'd: 767.2049 found: 767.2061
11D		Calc'd: 769.1842 found: 769.1817


- 40 -

Examples 11A -11D:

Prepare the desired compounds by procedures similar to Example 10, using D-N-Boc-aspartic acid benzyl ester in place of L-N-Boc-aspartic acid methyl ester.

5

EXAMPLE 12



Ex.	R ²⁶	HRMS (FAB, M+H ⁺)
12A	H-	Calc'd: 628.1416 found: 628.1434
12B		Calc'd: 714.1784 found: 714.1765
12C		Calc'd: 686.1471 found: 686.1482
12D		Calc'd: 687.1601 found: 687.1603
12E		Calc'd: 755.2049 found: 755.2047
12F		Calc'd: 714.1784 found: 714.1776
12G		Calc'd: 728.1940 found: 728.1945
12H		Calc'd: 713.1943 found: 713.1945
12I	H ₃ C-	Calc'd: 642.1572 found: 642.1562

Example 12A:

Step 1: Dissolve the product of Preparation 8, Step 1 (2.7 g, 8.1 mmol) in CH₂Cl₂ (40 mL), treat with 4 M HCl in dioxane (40 mL, 160 mmol) and stir for 2 h. Remove solvent under reduced pressure to yield a crude product. Re-dissolve the product in THF (45 mL), treat with carbonyldiimidazole

- 41 -

(2.26 g, 13.9 mmol) and reflux for 24 h. Remove solvent under reduced pressure and dilute with CH₂Cl₂ and NaHCO₃. Separate the organic layer, concentrate and purify the mixture with column chromatography using CH₂Cl₂ and CH₃OH with NH₃ (96:4) to give 1.8 g product.

5 Step 2: Treat the product of Step 1 by a procedure similar to Example 1, Step 3 to give the product.

Example 12B:

Step 1: Use a procedure described in Preparation 11, substituting 2-amino-ethanol for 3-amino-1-propanol to obtain the product.

10 Step 2: Treat the product of Step 1 by a procedure similar to Preparation 12A using glycine ethyl ester in place of methylamine.

Step 3: Treat the product of Step 2 by a procedure similar to Example 1, Step 3, using acid deprotection (HCl in CH₂Cl₂) in place of hydrogenation.

Example 12C:

15 Hydrolyze the product of Example 12B in a manner similar to Example 4A to give the desired product.

Examples 12D and 9E:

Treat the product of Example 12C by an amidation procedure similar to that described in Example 4E to give the title product.

20 Example 12F:

Step 1: Use the procedure of Preparation 11, substituting 2-aminoethanol for 3-amino-1-propanol.

Step 2: Treat the product of Step 1 using a procedure similar to Example 6L, Steps 2-4, to obtain the title compound.


25 Examples 12G-12H:

Treat the product of Example 12F using a procedure similar to Examples 6M and 6N to obtain the title compounds.

Example 12I:

30 Treat the product of Example 12F, Step 1, using a procedure similar to Example 6P to obtain the title compound.

EXAMPLE 13



- 42 -

Ex.	Z	MS
13A		Calc'd: 643.1412 found: 643.1419
13B		Calc'd: 659.1362 found: 659.1363


Example 13A:

Treat the product of Preparation 10 using a procedure similar to Example 1, Step 3 to yield the title compound.

Example 13B:

5 Treat the product of Example 13A using a procedure similar to that described in Preparation 12I-12L to yield the title compound.

EXAMPLE 14



Ex.	R1	MS (FAB): m/e
14A		Calc'd: 757.1954 found: 757.1945
14B		Calc'd: 771.2111 found: 771.2099
14C		Calc'd: 829.2278 found: 829.2269

EXAMPLE 14A:

10 Step 1: Treat 3,5-dichloro-N-[3-(3,4-dichlorophenyl)-2-[[hydroxyimino]-6-methyl-5-heptenyl]-N-methylbenzamide (4.2g, 8.6 mmol) in dry DMF(40 mL) at 0°C with KHMDS (0.5 M, toluene, 19 mL) keeping the internal temperature to <5°C. After stirring for 30 min, add bromoacetonitrile (655 µL, 9.4 mmol) and stir for 10 min. Pour the mixture into EtOAc (150 mL)/sat NaHCO₃ (75 mL). Extract the aqueous layer, wash the combined organic layers with brine, dry with Na₂SO₄ and concentrate in vacuo.

15

- 43 -

Purify by silica gel chromatography eluting with hexane/EtOAc to obtain 3.83 g (85%) of the nitrile as a colorless foam.

Step 2: Cool a solution of the olefin (3.83 g) from step 1 (in dry CH_2Cl_2 (50mL) to -78°C and treat with ozone for 7 min. Treat the solution with 5 dimethylsulfide (5.3 mL, 72.6 mmol, 10 eq). Allow the solution to warm to 23°C and stir for 2.5h. Dilute the solution with CH_2Cl_2 (50 mL) and wash with 10% $\text{Na}_2\text{S}_2\text{O}_4$. Wash the organic layers with brine, dry with Na_2SO_4 and concentrate in vacuo to give the aldehyde.

Step 3: Treat the product of step 2 using a procedure similar to Example 6FF.

10 Step 4: Treat the product of step 3 using a procedure similar to that of Example 6GG to obtain the corresponding hydroxyamidine.


EXAMPLE 14B:

Treat Example 14A using a procedure similar to that of Example 14A, step 1, using LHMDS in place of KHMDS and CH_3I as the alkylating agent to obtain the title compound.

EXAMPLE 14C:

Treat the product of Example 14A using a procedure similar to that of Example 14A, step 1, and then step 4 to give the desired compound.

EXAMPLE 15



20

Ex.	R ¹	HRMS (FAB): m/e
15A		Calc'd: 700.1739 found: 771.2099
15B		Calc'd: 685.1630 found: 685.1627

EXAMPLE 15A:

Use a procedure similar to that of Example 14A using the product of example 6O, step 1 as the piperidine in the reductive amination for step 3. Proceed to step 4 to give the title compound.

25


EXAMPLE 15B:

Use a procedure similar to that for Example 6A using methylbromoacetate in place of bromoacetonitrile. Proceed through the reductive amination with the product of Example 6O, step 1 to give the

- 44 -

methyl ester. Stir the resulting methyl ester with CH₃OH saturated with NH₃ for 18h. Concentrate in vacuo and purify by silica gel chromatography to give the title compound.


EXAMPLE 16



5

Treat the product of Example 14A, step 3 to a procedure similar to that of Example 6GG to give the title compound. HRMS (FAB, m/e):
Calc'd: 772.2063; found: 772.2059.

EXAMPLE 17



10

Step 1: Using a procedure similar to Preparation 12C-12H and substituting glycine methylester for the appropriate amine, prepare the corresponding cyclic urea/Boc piperidine.

Step 2: Using a procedure similar to Example 4A, hydrolyze the methyl ester to the carboxylic acid.


Step 3: Using a procedure similar to Example 4B to prepare the corresponding pyrrolidine amide.



Step 4: Using a procedure similar to Preparation 12A, step 3, deprotect the Boc group and isolate the free base of the resulting piperidine.

Step 5: Use the product of step 4 in a procedure similar to Example 14A, steps 3 and 4 to prepare the title compound. HRMS (FAB, M+H⁺): Calc'd: 811.2424; found: 811.2441.

- 45 -

EXAMPLE 18



Ex.	R ²⁶	HRMS (FAB, M+H ⁺)
18A	H	Calc'd: 676.1416 Found: 676.1389
18B	CH ₃ -	Calc'd: 692.1543 Found: 692.1558
18C		Calc'd: 748.1627 Found: 748.1621
18D		Calc'd: 734.1471 Found: 734.1487

Example 18A:


Treat 4-(2-keto-1-benzimidazolinyl)-piperidine and the product of Preparation 2 using the procedure of Example 2, Step 2, to give the title compound.

Examples 18B-18D:

Treat the product of Example 18A using the procedure in Examples 9B, 9C and 9D to give the title compounds.

10

EXAMPLE 19



Ex.	R ²⁶	HRMS (FAB, M+H ⁺)
19A	CH ₃ O(CH ₂) ₂ ⁻	Calc'd: 772.1852 Found: 772.1859
19B	CH ₃ O(CH ₂) ₂ NHC(O)CH ₂ ⁻	Calc'd: 805.2206 Found: 805.2195

Example 19A:

Step 1: Treat Boc-4-(2-keto-1-benzimidazolinyl)-piperidine (3.0 g, 9.46

- 46 -

mmol) with a preheated mixture of NaOH (1.14 g, 28.2 mmol), K₂CO₃ (2.61 g, 18.9 mmol) and nBuNHSO₄ (0.305 g, 0.9 mmol) in toluene (75 ml) for 30 min., add 2-bromomethoxyethane (1.33 ml, 14.2 mmol) and heat at 80 °C for an additional hour. Upon cooling, treat the mixture with water and

5 EtOAc, adjust pH to 7 using 10% citric acid. Extract with EtOAc, dry the organic layer with Na₂SO₄ and concentrate in vacuo to give a crude product.

Step 2: Deprotect the Boc group of the product of Step 1 using a similar procedure as in Preparation 12A, Step 3. Treat the product using a

10 procedure similar to Example 1, Step 3B, using the corresponding optically pure aldehyde (prepared as in Preparation 1) to give the desired product.

Example 19B: Use a procedure similar to that of Example 18C using the corresponding aldehyde (prepared as in Preparation 1) to give a product. Dissolve the product (0.5 g, 0.655 mmol) in 2-methoxyethylamine (10 ml),

15 and heat at 60 °C for 24 h. Upon cooling, treat the mixture with water and EtOAc. Extract with EtOAc, dry the organic layer with Na₂SO₄ and concentrate in vacuo to give a crude product. Purify by silica gel chromatography, eluting with CH₂Cl₂/CH₃OH gradient elution (99:1 – 97:3) to obtain 0.277 g of the desired product.

20

Compounds of formula I have been found to be antagonists of NK₁ and/or NK₂ and/or NK₃ receptors, and are therefore useful in treating conditions caused or aggravated by the activity of said receptors.

The *in vitro* and *in vivo* activity of the compounds of formula I can be determined by various procedures known in the art, such as a test for their ability to inhibit the activity of the NK₁ agonist Substance P, an isolated hamster trachea NK₂ assay, a test of the effect of NK₁ antagonists on Substance P-induced airway microvascular leakage, measurement of NK₂ activity *in vivo* in guinea pigs, measurement of bronchoconstriction due to NKA, and neurokinin receptor binding assay(s). NK₃ activity is determined by following a procedure similar to that described in the literature, e.g., *Molecular Pharmacol.*, 48 (1995), p. 711-716. Typical procedures for determining NK₁ and NK₂ activity are described in U.S. 5,696,267, incorporated herein by reference.

35 % Inhibition of neurokinin agonist activity is the difference between the percent of maximum specific binding (MSB) and 100%. The percent of MSB is defined by the following equation, wherein "dpm" is disintegrations per minute:

- 47 -

$$\% \text{ MSB} = \frac{(\text{dpm of unknown}) - (\text{dpm of nonspecific binding})}{(\text{dpm of total binding}) - (\text{dpm of nonspecific binding})} \times 100$$

It will be recognized that compounds of formula I exhibit NK₁, NK₂ and/or NK₃ antagonist activity to varying degrees, e.g., certain compounds have strong NK₁ antagonist activity, but weaker NK₂ and NK₃ antagonist activity, while others are strong NK₂ antagonists, but weaker NK₁ and NK₃ antagonists. While compounds with approximate equipotency are preferred, it is also within the scope of this invention to use compounds of with unequal NK₁/NK₂/NK₃ antagonist activity when clinically appropriate.


Using the test procedures known in the art, the following data (% inhibition or Ki) were obtained for preferred and/or representative compounds of formula I:

Ex.	Ki (NK ₁) (nM)	Ki (NK ₂) (nM)	Ki (NK ₃) (nM)
5B	0.9	2.8	---
6E	1.0	1.0	1.5
6K	0.5	0.8	0.5
6Y	0.4	0.4	0.4
8A	1.1	0.7	1.2
10B	2.9	28.9	34.6
11A	0.8	1.0	1.9
7F	1.8	0.4	3.8
16	0.4	0.4	0.7
18A	1.2	1.0	9.8
6M	0.9	0.5	0.3
6S	1.0	0.9	2.1

Compounds of the present invention exhibit a range of activity: percent inhibition at a dosage of 1μM ranges from about 0 to about 100% inhibition of NK₁ and/or about 0 to about 100% inhibition of NK₂. Preferred are compounds having a Ki ≤20nM for the NK₁ receptor. Also preferred are compounds having a Ki ≤20nM for the NK₂ receptor. Another group of preferred compounds are those having a Ki ≤20nM for each of the NK₁ and NK₂ receptors.

We claim:

1. A compound represented by the structural formula



5 or a pharmaceutically acceptable salt thereof, wherein:

a is 0, 1, 2 or 3;

b and d are independently 0, 1 or 2;

R is H, C₁₋₆ alkyl, -OR⁶ or -F;

A is =N-OR¹ or =N-N(R²)(R³);

10 when d is not 0, X is a bond, -C(O)-, -O-, -NR⁹-, -S(O)_e-,

-N(R⁶)C(O)-, -C(O)N(R⁶)-, -OC(O)NR⁶-, -OC(=S)NR⁶-, -N(R⁶)C(=S)O-,

-S(O)₂N(R⁶)-, -N(R⁶)S(O)₂-, -N(R⁶)C(O)O-, -OC(O)- or -N(R⁶)C(O)NR⁷-,

and

when d is 0, X is a bond or -NR⁶-;

15 T is H, R⁴-aryl, R⁴-heterocycloalkyl or R⁴-heteroaryl;

Q is R⁵-phenyl, R⁵-naphthyl or R⁵-heteroaryl;

R¹ is H, C₁₋₆ alkyl, -(C(R⁶)(R⁷))_n-G, -G², -(C(R⁶)(R⁷))_p-M-(C(R¹³)(R¹⁴))_n-G or -(C(R⁶)(R⁷))_p-M-(R⁴-heteroaryl);

20 R² and R³ are independently selected from the group consisting of H, C₁₋₆ alkyl, -(C(R⁶)(R⁷))_n-G, -G² and -S(O)_eR¹³; or R² and R³, together with the nitrogen to which they are attached, form a ring of 5 to 6 members, wherein 0, 1 or 2 ring members are selected from the group consisting of -O-, -S- and -N(R¹⁹)-;

25 R⁴ and R⁵ are independently 1-3 substituents independently selected from the group consisting of H, halogeno, -OR⁶, -OC(O)R⁶, -OC(O)N(R⁶)(R⁷), -N(R⁶)(R⁷), C₁₋₆ alkyl, -CF₃, -C₂F₅, -COR⁶, -CO₂R⁶, -CON(R⁶)(R⁷), -S(O)_eR¹³, -CN, -OCF₃, -OCHF₂, -NR⁶CO₂R¹⁶, -NR⁶COR⁷, -NR⁸CON(R⁶)(R⁷), NO₂, -N(R⁶)S(O)₂R¹³ or -S(O)₂N(R⁶)(R⁷); or adjacent R⁴ substituents or adjacent R⁵ substituents can form a -O-CH₂-O- group;

30 R⁶, R⁷, R⁸, R¹³ and R¹⁴ are independently selected from the group consisting of H, C₁₋₆ alkyl, C₂-C₆ hydroxyalkyl, C₁-C₆ alkoxy-C₁-C₆ alkyl, R¹⁵-phenyl, and R¹⁵-benzyl;

R⁹ is independently selected from the group consisting of R⁶ and -OR⁶;

- 49 -

or R⁶ and R⁷, or R⁷ and R⁹, together with the nitrogen to which they are attached, form a ring of 5 to 6 members, wherein 0, 1 or 2 ring members are selected from the group consisting of -O-, -S- and -N(R¹⁹)-;

5 R^{6a}, R^{7a}, R^{8a}, R^{9a}, R¹⁰ and R^{10a} are independently selected from the group consisting of H and C₁₋₆ alkyl;

R¹⁵ is 1 to 3 substituents independently selected from the group consisting of H, -OH, C_{1-C₆} alkyl, C_{1-C₆} alkoxy, C_{1-C₆} alkylthio, halogeno, -CF₃, -C₂F₅, -COR¹⁰, -CO₂R¹⁰, -C(O)N(R¹⁰)₂, -S(O)_eR^{10a}, -CN, -N(R¹⁰)COR¹⁰, -N(R¹⁰)CON(R¹⁰)₂ and -NO₂;

10 R¹⁶ is C₁₋₆ alkyl, R¹⁵-phenyl or R¹⁵-benzyl;

R¹⁹ is H, C_{1-C₆} alkyl, -C(O)N(R¹⁰)₂ or -CO₂R¹⁰;

n and p are independently 1-6;

G is selected from the group consisting of H, R⁴-aryl, R⁴-heterocycloalkyl, R⁴-heteroaryl, R⁴-cycloalkyl, -CH₂F, -CHF₂, -CF₃, -OR⁶, -N(R⁶)(R⁷), -COR⁶, -CO₂R⁶, -CON(R⁷)(R⁹), -S(O)_eR¹³, -NR⁶CO₂R¹⁶, -NR⁶COR⁷, -NR⁸CON(R⁶)(R⁷), -N(R⁶)S(O)₂R¹³, -N(R⁶)S(O)₂N(R³³)(R³⁴), -S(O)₂N(R⁶)(R⁷), -OC(O)R⁶, -OC(O)N(R⁶)(R⁷), -C(=NOR⁸)N(R⁶)(R⁷), -C(=NR²⁵)N(R⁶)(R⁷), -N(R⁸)C(=NR²⁵)N(R⁶)(R⁷), -CN, -C(O)N(R⁶)OR⁷, and -C(O)N(R⁹)-(R⁴-heteroaryl), provided that when n is 1, G is not -OH or -N(R⁶)(R⁷);

M is selected from the group consisting of a double bond, -O-, -N(R⁶)-, -C(O)-, -C(R⁶)(OR⁷)-, -C(R⁸)(N(R⁶)(R⁷))-, -C(=NOR⁶)N(R⁷)-, -C(N(R⁶)(R⁷))=NO-, -C(=NR²⁵)N(R⁶)-, -C(O)N(R⁹)-, -N(R⁹)C(O)-, -C(=S)N(R⁹)-, -N(R⁹)C(=S)- and -N(R⁶)C(O)N(R⁷)-, provided that when n is


25 1, G is not OH or -NH(R⁶); and when p is 2-6, M can also be -N(R⁶)C(=NR²⁵)N(R⁷)- or -OC(O)N(R⁶)-;

G² is R⁴-aryl, R⁴-heterocycloalkyl, R⁴-heteroaryl, R⁴-cycloalkyl, -COR⁶, -CO₂R¹⁶, -S(O)₂N(R⁶)(R⁷) or -CON(R⁶)(R⁷);


e is 0, 1 or 2, provided that when e is 1 or 2, R¹³ and R^{10a} are not H;

R²⁵ is H, C_{1-C₆} alkyl, -CN, R¹⁵-phenyl or R¹⁵-benzyl;

Z is



- 50 -



g, h and j are independently 0-2;

k is 1-4;

X¹ is -O-, -S- or -NR⁹-;

5 J is =O, =S, =NR⁹, =NCN or =NOR¹;

J¹ and J² are independently selected from the group consisting of two hydrogen atoms, =O, =S, =NR⁹ and =NOR¹;

10 R²⁶, R²⁷ and R²⁹ are independently selected from the group consisting of H, C₁₋₆ alkyl, -(C(R⁶)(R⁷))_n-G, -G², -C(O)-(C(R⁸)(R⁹))_n-G and -S(O)_eR¹³;

R²⁸ is H, -(C(R⁶)(R⁷))_t-G or -CON(R⁶)(R⁷);

t is 0, 1, 2 or 3, provided that when j is 0, t is 1, 2 or 3;

15 R³⁰ is 1-3 substituents independently selected from the group consisting of H, halogeno, -OR⁶, -OC(O)R⁶, -OC(O)N(R⁶)(R⁷), -N(R⁶)(R⁷), C₁₋₆ alkyl, -CF₃, -C₂F₅, -COR⁶, -CO₂R⁶, -CON(R⁶)(R⁷), -S(O)_eR¹³, -CN, -OCF₃, -NR⁶CO₂R¹⁶, -NR⁶COR⁷, -NR⁸CON(R⁶)(R⁷), NO₂, -N(R⁶)S(O)₂R¹³ or -S(O)₂N(R⁶)(R⁷); or adjacent R³⁰ substituents can form a -O-CH₂-O- group;

20 R³¹ is independently selected from the group consisting of H and C_{1-C₆} alkyl;

R³² is independently selected from the group consisting of H, -OH and C_{1-C₆} alkoxy; and

25 R³³ and R³⁴ are independently selected from the group consisting of H, C_{1-C₆} alkyl, R¹⁵-phenyl and R¹⁵-benzyl.

2. A compound of claim 1 wherein d is not 0 and X is -O-, -C(O)-, a bond, -NR⁹-, -S(O)_e-, -N(R⁹)C(O)-, -C(O)NR⁶ or -OC(O)NR⁶-.


3. A compound of claim 1 wherein T is R⁴-aryl or R⁴-heteroaryl.

30

4. A compound of claim 1 wherein Q is R⁵-phenyl,.


5. A compound of claim 1 wherein Z is

- 51 -



g and h are each 1; J is =O; j is 0; k is 1 or 2; and R²⁸ is H.


6. A compound of claim 1 wherein d is not 0 and X is -O-, -C(O)-, a bond, -NR⁹-, -S(O)_e-, -N(R⁶)C(O)-, -C(O)NR⁶ or -OC(O)NR⁶-, T is R⁴-aryl or R⁴-heteroaryl; Q is R⁵-phenyl; Z is



g and h are each 1; J is =O; j is 0; k is 1 or 2; and R²⁸ is H.


10 7. A compound of claim 6 wherein A is =N-OR¹, X is -N(R⁶)C(O)-, T is R⁴-aryl; Q is R⁵-phenyl; and R^{6a}, R^{7a}, R^{8a} and R^{9a} are each H.

8. A compound of claim 7 wherein Z is


























15 and k is 1 or 2.



















9. A compound of claim 1 selected from the group of compounds represented by the formula



20 wherein Z, R¹ and T are as defined in the table:

Z	R ¹	T
	-CH ₃	

	$-\text{CH}_3$	
	$-\text{CH}_2\text{C(O)NH}_2$	
	$-\text{CH}_2\text{C(NH}_2\text{)=NOH}$	
	$-\text{CH}_2\text{C(NH}_2\text{)=NOH}$	
	$-\text{CH}_2\text{C(NH}_2\text{)=NOH}$	
	$-\text{CH}_2\text{C(NH}_2\text{)=NOCH}_3$	
		
	$-\text{CH}_3$	
	$-\text{CH}_3$	
	$-\text{CH}_3$	
	$-\text{CH}_3$	

	-CH ₃	
	-CH ₃	
	-CH ₃	
	-CH ₃	
	-CH ₃	
	-CH ₃	
	-CH ₃	
	-CH ₃	
	-CH ₃	
	-CH ₃	
	-CH ₃	
	-CH ₃	
	-CH ₃	
	-CH ₃	
	-CH ₃	
	-CH ₃	
	-CH ₃	
	-CH ₃	
	-CH ₃	

- 55 -

<chem>CCN1CCN2C(=O)C(=O)N(CCCN3CCN(C)CC3)C2C1</chem>	-CH ₃	<chem>CCN1CCN(C)CC1c2ccc(Cl)c(Cl)c2</chem>
<chem>CCN1CCN2C(=O)C(=O)N(CCCN3CCN(C)CC3)C2C1</chem>	-CH ₃	<chem>CCN1CCN(C)CC1c2ccc(Cl)c(Cl)c2</chem>
<chem>CCN1CCN2C(=O)C(=O)N(CCCN3CCN(C)CC3)C2C1</chem>	-CH ₃	<chem>CCN1CCN(C)CC1c2ccc(C(F)(F)F)c(Cl)c2</chem>
<chem>CCN1CCN2C(=O)C(=O)N(CCCN3CCN(C)CC3)C2C1</chem>	-CH ₃	<chem>CCN1CCN(C)CC1c2ccc1c(c2)OCO1</chem>
<chem>CCN1CCN2C(=O)C(=O)N(CCCN3CCN(C)CC3)C2C1</chem>	-CH ₃	<chem>CCN1CCN(C)CC1c2ccc(Cl)c(Cl)c2</chem>
<chem>CCN1CCN2C(=O)C(=O)N(CCCN3CCN(C)CC3)C2C1</chem>	-CH ₃	<chem>CCN1CCN(C)CC1c2ccc(C)c(Cl)c2</chem>

	-CH ₃	
	-CH ₃	
	-CH ₃	
	-CH ₂ C(NH ₂)=NOH	
	-CH ₃	

10. A pharmaceutical composition comprising an effective amount of a compound of claim 1 and a pharmaceutically acceptable carrier.

11. The use of a compound of claim 1 for the preparation of a medicament for treating respiratory diseases, inflammatory diseases, skin disorders, ophthalmological disorders, addictions, central nervous system conditions, gastrointestinal disorders, bladder disorders, atherosclerosis, fibrosing disorders and obesity.

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
6 July 2000 (06.07.2000)

PCT

(10) International Publication Number
WO 00/39114 A3(51) International Patent Classification⁷: **C07D 401/04.**
401/14, 413/04, A61K 31/445, A61P 29/00(21) International Application Number: **PCT/US99/27953**(22) International Filing Date:
21 December 1999 (21.12.1999)

(25) Filing Language: English

(26) Publication Language: English


(30) Priority Data:
09/220,316 23 December 1998 (23.12.1998) US(71) Applicant: **SCHERING CORPORATION** [US/US];
2000 Galloping Hill Road, Kenilworth, NJ 07033-0530
(US).(72) Inventors: **REICHARD, Gregory, A.**; 4 Bahama Road,
Morris Plains, NJ 07950 (US). **SHIH, Neng-Yang**; 1
Maple Drive, North Caldwell, NJ 07006 (US). **WANG,**
Dasong; 941 Savitt Place, Apt. 3, Union, NJ 07083 (US).(74) Agents: **MAGATTI, Anita, W.** et al.; Schering-Plough
Corporation, Patent Dept. K-6-1 1990, 2000 Galloping Hill
Road, Kenilworth, NJ 07033-0530 (US).(81) Designated States (national): AE, AL, AM, AT, AU, AZ,
BA, BB, BG, BR, BY, CA, CH, CN, CR, CZ, DE, DK, DM,
EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG,
KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK,
MN, MX, NO, NZ, PL, PT, RO, RU, SE, SG, SI, SK, SL,
TJ, TM, TR, TT, TZ, UA, UZ, VN, YU, ZA.(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent
(AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent
(AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU,
MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM,
GA, GN, GW, ML, MR, NE, SN, TD, TG).**Published:**

— with international search report

(88) Date of publication of the international search report:
29 November 2001

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: SUBSTITUTED OXIMES AND HYDRAZONES AS NEUROKININ ANTAGONISTS

**WO 00/39114 A3**

heterocycloalkyl or heteroaryl; Q is phenyl, naphthyl or heteroaryl; R⁶ is H, alkyl, hydroxyalkyl, alkoxyalkyl, phenyl, and benzyl; R⁹ is R⁶ or -OR⁶, R^{6a}, R^{7a}, R^{8a} and R^{9a} are H or alkyl; Z is a nitrogen-containing heterocyclo group, e.g., piperidinyl, substituted by a heterocyclo- or heterocycloalkyl group; wherein phenyl, benzyl, aryl, heterocycloalkyl, heteroaryl and cycloalkyl groups are optionally substituted; methods of treating diseases such as asthma, cough, bronchospasm, depression, emesis, inflammatory diseases, and gastrointestinal disorders with said compounds, and pharmaceutical compositions comprising said compounds are disclosed.

(57) Abstract: Compound represented by structural formula (I) or a pharmaceutical acceptable salt thereof, wherein a is 0-3; b, d and e are 0-2; R is H, alkyl, F or -OR⁶; A is an optionally substituted oxime or hydrazone; d is not 0 and X is a bond, -C(O)-, -O-, -NR⁶-, -S(O)_e-, -N(R⁶)C(O)-, -C(O)N(R⁶)-, -OC(O)NR⁶-, -OC(=S)NR⁶-, -N(R⁶)C(=S)O-, -S(O)₂N(R⁶)-, -N(R⁶)S(O)₂-, -N(R⁶)C(O)O-, -OC(O)- or -N(R⁶)C(O)NR⁷-, or d is 0 and X is a bond or -NR⁶-, T is H, aryl, or

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 99/27953

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D401/04 C07D401/14 C07D413/04 A61K31/445 A61P29/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 96 34857 A (SCHERING) 7 November 1996 (1996-11-07) claims	1-5,10, 11
A	& US 5 688 960 A 18 November 1997 (1997-11-18) cited in the application ----	
A	WO 95 05377 A (ZENECA) 23 February 1995 (1995-02-23) claims; examples 3-22 ----	1,10,11
P,A	WO 99 26924 A (SCHERING) 3 June 1999 (1999-06-03) the whole document -----	1-5,10, 11

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the International filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

30 June 2000

Date of mailing of the international search report

11/07/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Francois, J

INTERNATIONAL SEARCH REPORTIn. ational application No.
PCT/US 99/27953**Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)**

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:

2. Claims Nos.: 1-8 (partly) because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210

3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.

2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:

4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

The additional search fees were accompanied by the applicant's protest.
 No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 1-8 (partly)

Present claims 1 to 8 relate to an extremely large number of possible compounds. Support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT is to be found, however, for only a very small proportion of the compounds/products/apparatus/methods claimed. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Consequently, the search has been carried out for those parts of the claims which appear to be supported and disclosed, namely those parts relating to the compounds prepared in the examples mentionned in the description and related homologous compounds and compounds of claim 9.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

Information on patent family members

Internat'nal Application No

PCT/US 99/27953

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO 9634857	A 07-11-1996	AU 706526	B	17-06-1999
		AU 5714096	A	21-11-1996
		BR 9608269	A	17-02-1999
		CA 2218913	A	07-11-1996
		CZ 9703424	A	15-07-1998
		EP 0823896	A	18-02-1998
		HU 9800840	A	28-08-1998
		JP 10506923	T	07-07-1998
		NO 975029	A	30-12-1997
		PL 323088	A	02-03-1998
		SK 147197	A	05-08-1998
		US 5696267	A	09-12-1997
		US 5688960	A	18-11-1997
		US 5840725	A	24-11-1998

WO 9505377	A 23-02-1995	AT 172971	T	15-11-1998
		AU 677091	B	10-04-1997
		AU 7388094	A	14-03-1995
		CA 2166800	A	23-02-1995
		CN 1129449	A	21-08-1996
		CZ 9600434	A	15-05-1996
		DE 69414398	D	10-12-1998
		DE 69414398	T	06-05-1999
		EP 0714392	A	05-06-1996
		ES 2123810	T	16-01-1999
		FI 960727	A	16-02-1996
		HU 75113	A	28-04-1997
		IL 110672	A	20-06-1999
		JP 9501439	T	10-02-1997
		NO 960630	A	16-02-1996
		NZ 269575	A	24-11-1997
		PL 313075	A	27-05-1996
		SK 21096	A	05-02-1997
		US 5990130	A	23-11-1999
		US 5567700	A	22-10-1996
		US 5861392	A	19-01-1999
		ZA 9406142	A	17-02-1995

WO 9926924	A 03-06-1999	AU 1450299	A	15-06-1999
		ZA 9810550	A	16-05-1999